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GENERAL ABSTRACT 
Stenotrophomonas maltophilia is increasingly emerging as an opportunistic pathogen of 
global concern. Due to its inherent resistance to several classes of antibiotics including 
carbapenems and its ability to acquire mobile resistance elements, treatment of infections 
caused by S. maltophilia is a constant challenge for clinicians. Trimethoprim-
sulphamethoxazole (TMP-SMX) is the generally accepted antibiotic of choice for the 
treatment of infections caused by this organism, but resistance to the drug is increasingly 
being reported; hence, the need for alternative therapeutic options. In this study, the 
antimicrobial susceptibility profile of 110 commensal S. maltophilia isolates obtained from 
Nkonkobe municipality, Eastern Cape Province, Republic of South Africa was investigated. 
Twenty-one antibiotics including TMP-SMX and the newer fluoroquinolones; levofloxacin, 
gatifloxacin and moxifloxacin were included in the antibiotic  panel. About 63.4% of the 
isolates were susceptible to TMP-SMX with a resistance rate of 28.2%. The fluoroquinolones 
were more effective with susceptibilities ranging from 76% to 94.7%. Resistance to the 
fluoroquinolones ranged from 1.3% to 2.7%. Levofloxacin was the most effective 
fluoroquinolone tested. Phenotypic dectection of extended spectrum β-lactamases (ESBLs) 
showed double disc synergy test (DDST) positivity in 59.5% of the isolates. Cefepime was 
the most sensitive indicator cephalosporin in the DDST with 77.3% of suspected ESBL-
producing isolates showing cefepime-clavulanic acid synergy. Isolates exhibited nine 
different ESBL phenotypes, however, PCR amplification of the bla genes revealed four 
isolates that possessed genes belonging to the CTX-M group (CTX-M-1 and CTX-M-8 
groups). ESBL genes are usually carried on mobile elements such as plasmids and 
transposons which may also bear genes that mediate resistance to aminoglycosides, 
tetracyclines, TMP-SMX and fluoroquinolones. ESBL positive isolates appeared more 
susceptible to the fluoroquinolones compared to TMP-SMX but there was no significant 
xi 
 
relationship between ESBL production and susceptibility to these drugs (p > 0.05). The 
newer fluoroquinolones are a possible alternative treatment option for S. maltophilia 
infections in this environment but further studies and clinical investigations are needed to 
determine the in vivo efficacy of these drugs.  
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CHAPTER ONE 
GENERAL INTRODUCTION 
The struggle between antibiotics and microorganisms dates as far back as the discovery of 
antibiotics themselves (Levy and Marshall, 2004; Tenover, 2006; Davies and Davies; 2010; 
D’Costa et al., 2011). Following Fleming’s discovery of the penicillin-producing mould, 
tremendous progress has been made in the last seven decades in the development of new 
antimicrobial agents. The β-lactam group which includes broad spectrum penicillins, narrow 
and extended spectrum cephalosporins, monobactams and carbapenems are among the most 
widely prescribed all over the world because of their efficacy and low toxicity (Elander, 
2003). However, even before penicillin was introduced for clinical use in the late 1930s, 
Abraham and Chain (1940) reported their discovery of an enzyme called penicillinase which 
could inactivate penicillin and as succinctly described by Dr Lederberg in his article, the 
future may very well remain a battle between “our wits and their genes” (Lederberg, 2000). 
In recent times, many authors, scientists and clinicians have expressed fears that infectious 
pathogens presently kept in check by the use of antibiotics will again become major sources 
of mortality (Nwosu, 2001; Livemore, 2007). Modern medical procedures such as transplants 
and immunosuppressive treatments which depend heavily on our ability to treat infection may 
collapse (Livermore, 2009). 
The indiscriminate, heavy use of the β-lactam antibiotics both for medical and non-
medical purposes has played a monumental role in the emergence of resistant bacteria 
(Nwosu, 2001; Levy and Marshall, 2004). This is particularly so with the employment of 
antibiotics in agriculture, animal and livestock rearing and the sale of antibiotics over the 
counter especially in some developing countries. Incorrect prescription and use of antibiotics 
by both medical personnel and the general public have also been a major contributory factor 
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(Nwosu, 2001; Perchere, 2001; Todar, 2008). The β-lactams usually act by inhibiting the 
penicillin-binding proteins which catalyse the final cross-linking of peptidoglycan in the 
bacterial cell wall leading to weakening of the cell wall and eventually lysis and cell death 
(Ghuysen, 1991; Bayles, 2000; Bush, 2001). The production of β-lactamases by the bacteria, 
however, leads to hydrolysis of the antibiotics and ineffective compounds (Bush, 2001). 
Gram-negative commensal and/or opportunistic pathogens are of importance and 
interest to clinicians. Though these organisms are thought to have low inherent pathogenicity, 
they are gradually becoming a problem in intensive care units worldwide (Livermore, 2009). 
These bacteria have evolved from being multi-drug resistant (resistance to three or more 
antimicrobial groups) to extreme drug resistance (susceptibility to two or fewer classes of 
antibiotics) and now to pan drug resistance (diminished susceptibility to all classes) (Senekal, 
2010). This might be due to the evolution of resistance genes as new members of the β-
lactam group of antibiotics have been developed with species shifts in favour of β-lactamase 
producers (Pfaller and Segreti, 2006). This has also occurred among the Gram-negative 
opportunists with organisms such as Enterobacter spp. and Pseudomonas aeruginosa having 
become more common hospital pathogens in the last few decades. Many of these Gram-
negative organisms possess naturally occurring chromosomally encoded β-lactamases which 
are thought to have developed as a result of selective pressure exerted by β-lactam producing 
soil microorganisms (Ghuysen, 1991). Antibiotic resistance genes apart from being 
chromosomal can also be carried on mobile genetic elements, such as plasmids and integrons, 
which facilitate the transfer of resistance between different species of bacteria by 
transformation, conjugation and transduction (Nwosu, 2001; Madigan et al., 2003; 
Livermore, 2007). It is therefore imperative to evaluate and monitor resistance genes in 
commensal, pathogenic and environmental bacteria in order to assess the environmental 
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resistance pool and better understand the ecology of antibiotic resistance (Goni-Urriza et al., 
2000; Ammore et al., 2001). 
The mechanisms of resistance in Gram-negative bacteria can be as a result of reduced 
accumulation of the drugs within cells subsequent to loss of porins or up-regulation of the 
bacterial efflux systems or both; but the most common cause of resistance against β-lactam 
antibiotics is the production of β-lactamases (Bonnet, 2004; Jacoby and Munoz-Price, 2005). 
According to Jones (2001), “the most important resistance problems that impact on 
nosocomial infections are extended spectrum β-lactamases (ESBLs) in Klebsiella 
pneumoniae, Escherichia coli and Proteus mirabilis, high level third generation 
cephalosporin (AmpC) β-lactamase resistance among Enterobacter and Citrobacter freundii 
and multi-drug resistant P. aeruginosa, Acinetobacter spp. and S. maltophilia”. 
Infections caused by multi-drug resistant Gram-negative bacteria, especially extended 
spectrum β-lactamase producers, are associated with higher mortality and morbidity (Rahal, 
2000; Salma, 2008). This often leads to higher healthcare costs compared with their drug 
susceptible counterparts due to longer intensive care unit stay and total length of stay in 
hospital, especially when ineffective empirical antimicrobial therapy is prescribed (Daxboeck 
et al., 2006; Salma, 2008; Tan et al., 2008; Wright and Eiland III, 2008). The impact of 
antibiotic resistance in non-fermentative Gram-negative bacilli may be even more significant 
because of their tendency to cause infections in intensive care and immunocompromised 
patients and the lack of effective antibiotics against the most resistant organisms currently 
and even in the future (Livermore, 2007; Tan et al., 2008). 
S. maltophilia is one of these nosocomial pathogens that have garnered interest 
because of evidence of its increasing role in nosocomial and opportunistic infections 
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worldwide particularly in debilitated and immunocompromised persons (Denton and Kerr, 
1998; Betriu et al., 2002; Koseoglu et al., 2004; McGowan, 2006). It has been suggested that 
this increase is due to expansion of the patient population at risk due to advances in medical 
therapeutic interventions such as invasive therapeutic devices and increased utilization of 
broad spectrum antimicrobials (Senol, 2004; Al-Jasser, 2006b). S. maltophilia is inherently 
resistant to most β- lactam antibiotics including the carbapenems and aminoglycosides 
(Denton & Kerr, 1998; Friedmann et al., 2002). This multi-drug resistance has been 
attributed to several mechanisms including outer membrane protein alterations associated 
with efflux or reduced permeability and the production of multiple inducible β-lactamases 
(Looney, 2005; Toleman et al., 2007). 
Trimethoprim-sulfamethoxazole (TMP-SMX) is therefore, currently the 
recommended treatment of choice for serious S. maltophilia infection but its effect is only 
bacteriostatic and there have been reports of resistance to the drug (Hohl et al., 1991; Fang 
and Madinger, 1996; Denton and Kerr 1998; Toleman et al., 2007). The newer 
fluoroquinolones have however, been recommended as possible alternative treatment for 
infections caused by this organism. The improved availability and activity of the 
fluoroquinolones make them a suitable therapeutic option (Weiss et al., 2000). This study 
intends to compare the antimicrobial activity of the third and fourth generation 
fluoroquinolones and TMP-SMX against confirmed ESBL-producing strains of S. 
maltophilia in the Eastern Cape environment with the purpose of providing retrospective 
information on the in vitro susceptibility of the organism to fluoroquinolones as an alternative 
treatment option should this environmental commensal become implicated in nosocomial or 
community acquired infections.  
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Traditionally, studies on antibiotic resistance have focused mainly on clinically 
important pathogenic bacteria. Conversely, according to Wright (2007), scientists need to 
broaden their view to include the entire pan-microbial genome. This refers to resistance genes 
in pathogenic bacteria, non-pathogenic bacteria and even the study of genes that have the 
potential to become resistance genes (Wright, 2007; Jayaraman, 2009). D’Costa et al. (2006) 
in their study of antimicrobial resistance among Actinomycetes isolated from the soil 
resistome found that the isolates were resistant to an average of 7-8 antibiotics out of the 21 
tested. This is particularly significant because soil microbes have been an under-appreciated 
and under-reported reservoir of antibiotic resistance genes and because the majority of 
organisms in soil are unculturable, the resistance potential could be even greater. It is also 
impossible to rule out the horizontal transfer of genes from environmental organisms to 
pathogenic bacteria making it even more important to study the antibiotic resistome of these 
environments (Jayamaran, 2009). 
 
1.1 AIMS AND OBJECTIVES 
The main aim of this study was to compare the in vitro activity of the third and fourth 
generation fluoroquinolones (levofloxacin, gatifloxacin and moxifloxacin) and trimethoprim-
sulfamethoxazole against confirmed extended spectrum β-lactamase producing strains of 
Stenotrophomonas maltophilia found in the Eastern Cape environment. 
Specific objectives include: 
 To determine the antibiogram characteristics of S. maltophilia isolates obtained from 
plants rhizosphere samples in the Nkonkobe district municipality of the Eastern Cape 
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Province, South Africa as part of the culture collection of the Applied and 
Environmental Microbiology Research Group (AEMREG). 
 To select for putative extended spectrum β-lactamase producing S. maltophilia isolates. 
 To assess the resistance genes responsible for ESBL production in confirmed isolates. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Stenotrophomonas maltophilia 
Stenotrophomonas maltophilia, formerly known as Pseudomonas maltophilia and then 
Xanthomonas maltophilia was eventually classified as the sole species of the genus 
Stenotrophomonas following a long period of uncertainty about its taxonomic classification 
(Palleroni and Bradbury, 1993). It was first isolated in 1943 and was named Bacterium 
bookeri at the time. The genus name derived from the Greek words stenus meaning narrow, 
trophus meaning one who feeds and monas meaning a unit; was intended to demonstrate the 
limited nutritional status of the organism (Palleroni and Bradbury, 1993; Berg et al., 1999) 
but several studies have subsequently shown that the genus is “capable of great metabolic 
diversity and intraspecific heterogeneity” (Ryan et al., 2009) 
Although only one species was described initially, the genus currently comprises of 
eleven species: S. maltophilia (Hugh, 1981) (Palleroni and Bradbury, 1993), S. 
nitritireducens (Finkmann et al., 2000), S. rhizophilia (Wolf et al., 2002), S. acidaminiphilia 
(Assih et al., 2002), S. koreensis (Yang et al., 2006), S. terrae and S. humi (Heylen et al., 
2007), S. gisengisoli (Kim et al., 2010), S. daejeonensis (Lee et al., 2010), S. panacihumi (Yi 
et al., 2010) and S. pavanii (Ramos et al., 2011). S. maltophilia is the dominant species of the 
genus and is the only one that has been implicated in human disease (Paton et al., 1994; 
Coenye et al., 2004). 
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2.1.1 Morphology, Culture and Biochemical characterisitics 
Stenotrophomonas are straight or slightly curved non-sporulating Gram-negative bacilli 
measuring 0.5 to 1.5µm long. This organism is motile with several polar flagella and may 
produce fimbriae. The colonies appear as smooth, glistening with entire margins and are 
white, greyish or pale yellow (Denton and Kerr, 1998). S. maltophilia occur singly or in pairs 
and do not accumulate poly-β-hydroxybutyrate as intracellular granules (Denton and Kerr, 
1998). 
S. maltophilia are obligate aerobes and do not grow at temperatures lower than 5
o
C or 
higher than 40
o
C. Growth is optimal at 35
o
C. Most strains require methionine or cysteine for 
growth but this is not a universal requirement. Some strains exhibit a brownish discolouration 
on clear media which has been attributed to a secondary chemical reaction of extracellular 
products but this is more intense when these strains are incubated at 42
o
C (Blazevic, 1976) or 
grown on media with high tyrosine content (Hugh and Gilardi, 1980). S. maltophilia is not 
considered to be beta-haemolytic but some studies have shown that when cultured on blood 
agar both aerobically and anaerobically, it produces a greenish hue (alpha haemolysis) around 
confluent growth (Bonny et al., 2010). 
It carries somatic O antigens and flagellar H antigens which have been identified and 
used in typing S. maltophilia in epidemiological studies and the structure of the most 
common serotype; O3 has been determined along with six others (Denton and Kerr, 1998). 
Several studies have reported cross-reactions of the somatic antigens with the O antigens of 
other organisms including Brucella sp. (Corbel et al., 1984), Renibacterium salmoninarum 
(Brown et al., 1995), Legionella pneumophilia and Shigella dysenteriae type 8 (Bonny et al., 
2010). 
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S. maltophilia also possesses a unique fatty acid profile which has been of use in 
identification of the bacterium (Norman et al., 1997). Studies by Moss et al. (1973) revealed 
the presence of large amounts of 13-methyltetradecanoic acid (a branched chain 15-carbon 
fatty acid) and three additional branched chain hydroxyl-fatty acids not present in the other 
bacteria investigated. 
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Table 2.1: Biochemical characteristics of Stenotrophomonas maltophilia (Denton and 
Kerr, 1998). 
TEST REACTION 
Indophenol oxidase - 
Catalase + 
Growth  
 5oC 
 18oC 
 37oC 
 
- 
+ 
+ 
Motility 
 18oC 
 37oC 
 
+ 
V 
Indole - 
Lysine hydroxylase + 
Orthinine decarboxylase - 
Methyl red - 
Voges-Proskauer - 
Hydrogen sulphide - 
Reduction of nitrate to nitrite V 
Citrate V 
Phenylalanine deaminase - 
β-Galactosidase (ONPG) V 
Hydrolysis 
 Esculin 
 Gelatin 
 Tween 80 
 DNA 
 Starch 
 Urea 
 
+ 
+ 
+ 
+ 
- 
- 
Carbon sources for growth 
 Adonitol  
 Arabinose 
 β-hydroxybutyrate 
 Cellobiose 
 Dulcitol  
 Glucose 
 Fructose  
 Galactose  
 Mannitol 
 Rhamnose  
 Salicin  
 Sorbitol 
 Trehalose 
 
- 
- 
- 
V 
- 
+ 
V 
- 
V 
- 
- 
- 
- 
+ = >85% strains positive v = 16 to 84% strains positive - = ≤ 15% strains positive  
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2.1.2 Habitat 
S. maltophilia is ubiquitous and found in a wide variety of environments and geographical 
areas. It has been isolated from different water sources including rivers, wells, lakes, bottled 
water and sewage (Kerr and Wilkinson, 1998; Hauben et al., 1999; Whitby et al., 2000). It is 
also present in a variety of soil and plant rhizosphere environments like grasses, sugarcane 
and palms, wheat, cabbage, rape, mustard, corn, beet, bananas, cotton, beans, tobacco, rice 
paddies, citrus plants, orchids, irises, legume inoculants that use non-sterile peat as a carrier 
and stored timber (Denton and Kerr, 1998). There have been reports of isolation from oil 
brines and other related materials from oil fields in Japan (Iizuka and Komgata, 1963) and it 
has also been reported to grow on loofah sponges (Bottone et al., 1994). It can be found in 
food sources like frozen fish, milk, poultry eggs and lamb carcasses (Hugh and Ryschenkow, 
1961; Juffs, 1973). 
Over the years, S. maltophilia has evolved into an important nosocomial pathogen 
(Denton and Kerr, 1998; Whitby et al., 2000; Koseoglu et al., 2004). It has been isolated 
from a variety of nosocomial sources which include: blood sampling tubes, central 
venous/arterial pressure monitors, contact lens care systems, deionized water dispensers, 
dialysis machines, disinfectant solutions, hands of health care personnel, hydrotherapy pools, 
ice-making machines, nebulizers and inhalation therapy equipment, necropsy specimens, 
oxygen analysers, oxygen humidifier reservoirs, shaving brushes, shower heads, sink traps, 
water faucets, sphygmomanometers and ventilator circuits (Denton and Kerr, 1998; Senol, 
2004). 
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2.1.3 Pathogenicity 
S. maltophilia had long been thought to be an organism with limited pathogenicity because of 
the failure to differentiate colonisation from infection and the inability to directly associate 
infections with mortality in affected patients (Looney, 2005). The organism was often linked 
with clinically overt infection only when acting in synergy with other more virulent 
pathogens and attempts to induce infection in an experimental animal model by injecting 
whole bacteria into mice failed to cause serious sepsis. In addition, the organism has been 
distinguished more for its multiple antibiotic resistance than for invasiveness and tissue 
destruction (Looney, 2005) 
S. maltophilia produces several extracellular enzymes including DNase, RNase, 
arbutinase, acetase, esterases, lipases, mucinase, acid and alkaline phosphatases, 
phosphoamidase, leucine arylamidase, β-glucosidase, elastase and hyaluronidase; some of 
which have been associated with the pathogenesis of S. maltophilia infections (O’Brien and 
Davies, 1982; Travassos et al., 2004; Looney et al., 2009). The production of proteases and 
elastase plays a significant role in bacterial pathogenesis, participating in invasion, tissue 
damage and evasion of the host’s natural defences. Production of lipases seems to contribute 
to the virulence of some species associated with pulmonary infections, either by hydrolysing 
lipid-rich pulmonary tissue components or by triggering an intense inflammatory response 
(Travassos et al., 2004). 
Fimbriae or pili are important in the adherence of bacteria to epithelial cells for the 
initiation of colonisation or invasion of the host cells (Denton and Kerr, 1998). This process 
is mediated by fimbrial adhesins which aid the direct binding of bacteria to the target cells or 
indirect binding by the forming of cross linkages within the bacteria that aid colonisation. 
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The fimbriae produced by S. maltophilia have been found to aid its adhesion to epithelial 
cells and also inert surfaces resulting in biofilm formation (De Oliveira-Garcia et al., 2003). 
The formation of biofilms protects the bacteria from the hosts’ natural immune system and 
from inactivation by antimicrobial compounds. The ability of S. maltophilia to adhere to 
plastic and other abiotic surfaces such as medical implants and catheters and also its ability to 
survive in intravenous fluids and production of an extracellular elastase may contribute to the 
pathogenesis of intravenous line related infections (Denton and Kerr, 1998; De Oliveira-
Garcia et al., 2003). 
Production of an outer membrane lipopolysaccharide (LPS) is also an important 
virulence factor and this is supported by the possession of the spgM gene which codes for the 
LPS production and also confers resistance to complement-mediated killing on isolates that 
possess the gene (McKay et al., 2003). Finally, S. maltophilia also has the potential for 
indirect pathogenicity, as it can aid the virulence of other pathogens. It has been shown to 
modify the biofilm formation and polymyxin B sensitivity of P. aeruginosa (Livermore, 
2009). Kataoka et al. (2003) have also shown that β-lactamases produced by S. maltophilia 
can increase the survival of P. aeruginosa that are normally susceptible to imipenem when 
the two organisms grow in culture together.  
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2.1.4 Resistance mechanisms of Stenotrophomonas maltophilia 
S. maltophilia possess several mechanisms which contribute to its multi-drug resistant status. 
It is intrinsically resistant to various groups of antibiotics including β-lactams, carbapenems, 
quinolones, aminoglycosides, tetracyclines, disinfectants and heavy metals through the 
possession of multi-drug efflux pumps, low permeability of the outer membrane, 
chromosomal β-lactamases and aminoglycoside-modifying enzymes. It can also acquire 
resistance genes by the acquisition of integrons, transposons and plasmids (Toleman et al., 
2007; Looney et al., 2009). 
β-lactam resistance is mediated by the expression of two inducible β-lactamases, L1 
and L2. L1 is an Ambler class B zinc-dependent metalloenzyme that hydrolyses all classes of 
β-lactams except the monobactams while the L2 enzyme is an Ambler class A serine β-
lactamase which is inhibited by clavulanic acid (Kataoka et al., 2003). Other studies have, 
however, reported the production of other β-lactamases in S. maltophilia (Cullman and Dick, 
1990; Paton et al., 1994; Payne et al., 1994; Al-Naiemi et al., 2006; Lavigne et al., 2008). 
Resistance to TMP-SMX has been attributed to the presence of sul1 genes located on class 1 
integrons and sul2 genes carried on insertion sequence common region (ISCR) elements. 
Overexpression of efflux pumps and low outer membrane permeability are the features 
responsible for resistance to the quinolones (Looney et al., 2009). In addition to being an 
opportunistic pathogen in humans, S. maltophilia strains have also been used in 
biotechnology and in the control of plant pathogens but it has been demonstrated that all 
strains share the intrinsic resistance phenotype irrespective of whether they are clinical or 
environmental isolates (Berg et al., 1999; Sanchez et al., 2009). 
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2.1.5 Stenotrophomonas maltophilia as an opportunistic human pathogen 
Little is known about the origin of pathogenic strains of S. maltophilia responsible for 
nosocomial infections. Molecular studies done on nosocomial isolates suggest the 
environment may be a major source of acquisition of the bacteria by patients as identical 
strains have been found in both hospital and environmental sources (Muder, 2007) and 
genetic analysis suggests that S. maltophilia has adapted to human colonisation by losing 
certain plant pathogenic traits and gaining potential human virulence factors (Crossman et al., 
2008). It has been implicated in several different infections including urinary tract infections, 
ocular infections, respiratory tract infections, meningitis, bacteremia, skin and soft tissue 
infections often affecting immunocompromised patients and patients with cystic fibrosis. It 
can however, also cause community acquired infections (Heath and Currie, 1995; Denton and 
Kerr, 1998; Falgas et al., 2009). 
Significant risk factors that have been associated with S. maltophilia infections 
include: prolonged hospitalization, admission to intensive care unit, central venous 
catheterization, neutropenia, mechanical ventilation and prior antibiotic therapy (Vartivarian 
et al., 1994; Senol et al., 2002; Senol, 2004; Looney et al., 2009). It is also being increasingly 
reported in opportunistic infections affecting patients with HIV (Calza et al., 2003). 
Infections caused by S. maltophilia are difficult to treat because the organism is 
resistant to majority of the available broad spectrum antibiotics including most 
antipseudomonal β-lactam antibiotics, aminoglycosides and the older fluoroquinolones. It is 
particularly inherently resistant to the carbapenems (imipenem and meropenem) (Looney, 
2005) which gives it an increased chance of survival over other potential pathogens in the 
hospital environment (Avison et al., 2000). 
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The most active single drugs against the organism are ticarcillin/clavulanate and 
trimethoprim-sulfamethoxazole but TMP-SMX is still the recommended therapy of choice 
for the treatment of S. maltophilia infections (Hanberger et al., 2001). However the action of 
TMP-SMX is bacteriostatic and several studies have reported an increasing prevalence of S. 
maltophilia strains that show resistance to this drug of choice (Tsiodras et al., 2000; Gales et 
al., 2001; San Gabriel et al., 2004). The emergence of TMP-SMX resistance has prompted 
the use of the newer fluoroquinolones either alone or in combination with other antibiotics 
(Krueger et al., 2001; Friedman et al., 2002). A study by Weiss et al. (2000) reported better 
in vitro activity of the newer quinolones; trovafloxacin, clinafloxacin and moxifloxacin 
compared to ciprofloxacin and levofloxacin.  
 
2.2 EXTENDED SPECTRUM BETA LACTAMASES 
Extended spectrum β-lactamases (ESBLs) are a recent and increasingly important problem in 
the area of infectious diseases (Wright and Eiland III, 2008). Their production is the 
predominantly recognized mechanism of resistance to β-lactam antibiotics in clinically 
important Gram-negative bacteria (Bonnet, 2004; Bush and Jacoby, 2010). 
The TEM-1 enzyme was the first plasmid-mediated β-lactamase to be described 
originally in a single strain of E. coli isolated from the blood culture of a patient in Greece 
and the assignation TEM was derived from the patient’s name; Temoniera. Another plasmid-
borne β-lactamase was also found at about the same time in Klebsiella pneumoniae and E. 
coli and was designated SHV-1 (sulfhydryl variable) (Turner, 2005). The spread of the 
enzyme was facilitated by the fact that it is plasmid- and transposon-mediated. It is now 
found worldwide in several organisms including but not limited to members of the family 
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Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae and Neisseria 
gonorrhoeae (Bradford, 2001; Turner, 2005; Wright and Eiland III, 2008). The enzymes are 
thought to have evolved from penicillin binding proteins with which they show some 
sequence homology (Bradford, 2001). Many Gram-negative bacteria possess a naturally 
occurring chromosomally mediated β-lactamase which probably assists the bacteria in 
finding a niche when faced with competition from other bacteria that naturally produce beta-
lactams (Bradford, 2001; Turner, 2005). 
The discovery and spread of these enzymes drove the development and introduction 
of novel antibiotics of the β-lactam class by the pharmaceutical industry in an attempt to 
tackle the resistance problems posed by the newly discovered beta lactamases. However, new 
beta-lactamases emerged with the introduction of each new class of drugs. The development 
of the oxymino-cephalosporins was a major achievement and these drugs became the 
treatment of choice for serious Gram-negative infections because of resistance to hydrolysis 
by the TEM-1 and SHV-1 enzymes (Schwaber et al., 2005). The result has, however, been 
the development of a more diverse and potentially more devastating group of beta-lactamases 
which have progressed from ESBLs to AmpC enzymes (Wright and Eiland III, 2008). 
Resistance to the new expanded spectrum cephalosporins emerged rapidly and was 
first described in a K. pneumoniae isolate in Germany and was named SHV-2 because of its 
amino acid similarity to the SHV-1 enzyme. This and several other enzymes subsequently 
discovered were then named extended spectrum beta-lactamases (ESBLs) because of their 
ability to hydrolyse these expanded spectrum β-lactam antibiotics (Turner, 2005). 
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2.2.1 Classification of beta lactamases 
Beta-lactamases as a whole are classified according to two schemes: the Ambler molecular 
classification system and the Bush-Jacoby-Medieros functional classification system (Ambler 
et al., 1991; Bush et al., 1995). The Ambler classification divides the beta lactamases into 
four classes: A through D based on amino acid similarities. Classes A, C and D are referred 
to as serine beta lactamases because these enzymes hydrolyse their substrates by forming an 
acyl enzyme through the serine active site while the class B enzymes employ at least one 
active site zinc ion to hydrolyse their substrates and are therefore referred to as metallo-
enzymes (Bush and Jacoby, 2010). Though this structural classification appears to be the 
simplest way to classify this diverse group of enzymes, the functional classification based on 
their different substrate profiles assists in relating the properties of the enzymes to their 
clinical implications and observed antibiogram characteristics. 
In an attempt to more fully and efficiently describe the growing group of beta 
lactamase enzymes, Bush and Jacoby (2010) published an updated classification system 
(shown in Table 2.2) which is essentially an updated functional classification scheme that 
considers the substrate and inhibitor profiles while correlating the major groupings with the 
simpler molecular classification. This assists in grouping the enzymes in ways that relate with 
observed clinical phenotypes. The ESBLs are, therefore, defined as beta-lactamases capable 
of hydrolysing oxymino-cephalosporins that are inhibited by clavulanic acid and are placed in 
functional group 2be.  The majority of ESBLs have an active serine site and belong to the 
Ambler class A which have a molecular mass of approximately 29kDa and preferentially 
hydrolyse penicillins (Bradford, 2001).  
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Class A ESBLs consists of a heterogeneous molecular cluster which comprises beta-
lactamases that share 20 to 99% of their identities (Bradford, 2001). The enzymes are derived 
from the originally plasmid-mediated TEM-1/2 and SHV-1 penicillinases and differ from 
them by one to four point mutations. These mutations are responsible for the expanded 
hydrolytic spectra of the ESBLs. TEM and SHV ESBLs now consist of more than 500 
different types; most of which are ceftazidimases and are found worldwide (Bradford, 2001; 
Bonnet, 2004; Bush and Fisher, 2011). The class D enzymes also belong to group 2 and 
include the OXA-type ESBLs which are so called because they hydrolyse oxacillin but are 
poorly inhibited by clavulanic acid. OXA-type ESBLs are predominantly found in 
Pseudomonas aeruginosa but have also been reported in other Gram-negative bacteria 
(Deepthi and Deepthi, 2010). 
Many other non-TEM and non-SHV plasmid-mediated ESBLs have been reported. 
The most widespread of these are the CTX-M types which have been reported in organisms 
in every geographical area of the world (Bonnet, 2004; Paterson and Bonomo, 2005). CTX-M 
ESBLs are potent hydrolysers of cefotaxime from which this group of enzymes derive their 
name while minimum inhibitory concentration of ceftazidime may be in the susceptible 
range. It should, however, be noted that the same organism may have both SHV and CTX-M 
types and AmpC types which may alter the antibiotic resistance pattern (Paterson and 
Bonomo, 2005; Bush and Fisher, 2011).  
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 Table 2.2: Classification schemes for bacterial β-lactamases (Bush and Jacoby, 2010). 
Bush-
Jacoby 
group 
(2009) 
Bush-Jacoby-
Medeiros 
group (1995) 
Molecular 
class 
(subclass) 
Distinctive 
substrate(s) 
Inhibited by 
Defining characteristic(s) 
Representative 
enzyme(s) CA or 
TZB
a
 EDTA 
1 1 C Cephalosporins No No Greater hydrolysis of cephalosporins 
than benzylpenicillin; hydrolyzes 
cephamycins 
E. coli AmpC, P99, 
ACT-1, CMY-2, FOX-
1, MIR-1  
1e NI
b
 C Cephalosporins No No Increased hydrolysis of ceftazidime 
and often other oxyimino-β-lactams 
GC1, CMY-37 
2a 2a A Penicillins Yes No Greater hydrolysis of benzylpenicillin 
than cephalosporins 
PC1 
2b 2b A Penicillins, early 
cephalosporins 
Yes No Similar hydrolysis of benzylpenicillin 
and cephalosporins 
TEM-1, TEM-2, SHV-
1 
2be 2be A Extended-spectrum 
cephalosporins, 
monobactams 
Yes No Increased hydrolysis of oxyimino-β-
lactams (cefotaxime, ceftazidime, 
ceftriaxone, cefepime, aztreonam) 
TEM-3, SHV-2, CTX-
M-15, PER-1, VEB-1 
2br 2br A Penicillins No No Resistance to clavulanic acid, 
sulbactam, and tazobactam 
TEM-30, SHV-10 
2ber NI A Extended-spectrum 
cephalosporins, 
monobactams 
No No Increased hydrolysis of oxyimino-β-
lactams combined with resistance to 
clavulanic acid, sulbactam, and 
tazobactam 
TEM-50 
2c 2c A Carbenicillin Yes No Increased hydrolysis of carbenicillin PSE-1, CARB-3 
2ce NI A Carbenicillin, 
cefepime 
Yes No Increased hydrolysis of carbenicillin, 
cefepime, and cefpirome 
RTG-4 
2d 2d D Cloxacillin Variable No Increased hydrolysis of cloxacillin or 
oxacillin 
OXA-1, OXA-10 
2de NI D Extended-spectrum 
cephalosporins 
Variable No Hydrolyzes cloxacillin or oxacillin 
and oxyimino-β-lactams 
OXA-11, OXA-15 
2df NI D Carbapenems Variable No Hydrolyzes cloxacillin or oxacillin OXA-23, OXA-48 
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Bush-
Jacoby 
group 
(2009) 
Bush-Jacoby-
Medeiros 
group (1995) 
Molecular 
class 
(subclass) 
Distinctive 
substrate(s) 
Inhibited by 
Defining characteristic(s) 
Representative 
enzyme(s) CA or 
TZB
a
 EDTA 
and carbapenems 
2e 2e A Extended-spectrum 
cephalosporins 
Yes No Hydrolyzes cephalosporins. Inhibited 
by clavulanic acid but not aztreonam 
CepA 
2f 2f A Carbapenems Variable No Increased hydrolysis of carbapenems, 
oxyimino-β-lactams, cephamycins 
KPC-2, IMI-1, SME-1 
3a 3 B (B1) Carbapenems No Yes Broad-spectrum hydrolysis including 
carbapenems but not monobactams 
IMP-1, VIM-1, CcrA, 
IND-1 
  B (B3)     L1, CAU-1, GOB-1, 
FEZ-1 
3b 3 B (B2) Carbapenems No Yes Preferential hydrolysis of 
carbapenems 
CphA, Sfh-1 
NI 4 Unknown      
a CA, clavulanic acid; TZB, tazobactam.  
b NI, not included.  
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The other types of ESBLs that have been described include: PER, VEB, GES/IBC, 
TLO-1, and SFO-1 and BES-1 types. The PER type ESBLs share 25 to 27% similarity with 
the TEM- and SHV-types. These enzymes hydrolyse penicillins and cephalosporins 
effectively and are inhibited by clavulanic acid. These other ESBL types are not simple point 
mutations of any known beta-lactamases and have varying degrees of similarity with them. 
They have also been found in a wide variety of environments (Paterson and Bonomo, 2005). 
The GES/IBC ESBLs have been reported from hospital pathogens in South Africa and France 
(Weldhagen et al., 2003) but there is limited data on the epidemiology of ESBL-producing 
organisms in South Africa and Africa as a whole. Recent studies which characterized ESBLs 
from South Africa have however revealed the presence of a diverse number of enzymes in 
various organisms (Pitout et al., 1998; Hanson et al., 2001; Goviden et al., 2008; Ehlers et 
al., 2009, Peirano et al., 2011).  
 
2.2.2 TEM β-lactamases 
This group of β-lactamases was the first to be described in the 1960s and TEM-1 is the most 
common beta-lactamase responsible for resistance to β-lactam antibiotics in Gram-negative 
organisms worldwide (Ghuysen, 1991). It hydrolyses penicillins and the first generation 
cepahalosporins such as cephalothin and cephalodrine but has no activity against the 
extended spectrum cephalosporins. Its location on the Tn3 transposon and several 
transposition and rearrangement events has aided the migration into other species such as H. 
influenzae and N. gonorrhoeae (Livermore, 1995).  
TEM-2, the first derivative from TEM-1 had a single amino acid substitution which 
caused a shift in the isoelectric point from pI of 5.4 to 5.6 but had no effect on the substrate 
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profile. TEM-3, originally described in 1989 was the first variant with the ESBL phenotype 
and since then >90 additional derivatives have been described. The ESBL phenotype occurs 
as a result of several amino acid substitutions which include glutamate to lysine at position 
104, arginine to serine or histidine at position 164, glycine to serine at position 238 and 
glutamate to lysine at position 240. Different combinations of these substitutions result in 
subtle changes in the substrate profiles of the enzymes or a change in the isoelectric points 
which may range from pI 5.2 to 6.5 (Bradford, 2001). Figure 2.1 shows the relevant amino 
acid substitutions and the various derivative phenotypes  
 
Figure 2.1: Showing the common amino acid substitutions with the resulting TEM 
phenotypes. Adapted from Bradford P.A. (2001). 
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Laboratory mutations of TEM-1 that contain substitutions at positions other than 
those that occur naturally have been described (Bradford, 2001) but naturally occurring 
TEM-type ESBLs are thought to have been the result of varying selective pressure from 
several β-lactams rather than selection with a single agent (Blazquez et al., 2000). The ESBL 
phenotype changes the configuration of the active site of the enzyme enabling it to hydrolyse 
oxymino-cephalosporins while also enhancing its susceptibility to β-lactamase inhibitors such 
as clavulanic acid (Jacoby and Munoz-Price, 2005). Some TEM variants have been found to 
have ESBL type mutations identified together with those that confer resistance to β-
lactamases inhibitors but this combination is rare as inhibitor-resistant β-lactamases are 
inefficient in hydrolysing the extended spectrum cephalosporins (Jacoby and Munoz-Price, 
2005). Some derivatives have, however, been found to retain both activities at significant 
levels (Fiett et al., 2000). 
Although TEM-type β-lactamases are most often found in E. coli and K. pneumoniae, 
they are also found in other species of Gram-negative bacteria such as Enterobacter 
aerogenes, Morganella morganii, Proteus mirabilis, Proteus rettgeri, and Salmonella spp. 
(Palzkill et al., 1995, Morosini et al., 1995, Mugnier et al., 1996, Bonnet et al., 1999, 
Marchandin et al., 1999). They have also been reported in non-Enterobacteriaceae Gram-
negative bacteria like Pseudomonas aeruginosa (Bradford, 2001). 
 
2.2.3 SHV β-lactamases 
The SHV type ESBLs are probably the most commonly found in clinical isolates worldwide. 
About 50 derivatives of SHV-1 have been described with majority of them possessing an 
ESBL phenotype which is characterised by substitution of serine for glycine at position 238 
25 
 
and lysine for glutamate at position 240 (Al-Jasser, 2006a). These substitutions mirror those 
seen in TEM-type ESBLs at these positions (Bradford, 2001) and the serine residue is 
essential for the efficient hydrolysis of ceftazidime while the lysine residue is essential for the 
hydrolysis of cefotaxime (Huletsky et al., 1993). One variant, SHV-10 has been found to 
have an inhibitor-resistant phenotype with an additional substitution of glycine for serine at 
position 130 (Bradford, 2001). These enzymes have been described mostly in 
Enterobacteriaceae but also in P. aeruginosa and Acinetobacter spp. 
 
Figure 2.2:  Showing the common amino acid substitutions in the SHV-1 enzyme with the 
resulting SHV phenotypes. Adapted from Bradford P.A. (2001). 
 
2.2.4 CTX-M β-lactamases 
The CTX-M enzymes are a group of plasmid-mediated enzymes that preferentially hydrolyse 
cefotaxime with variable activity against ceftazidime. These β-lactamases are thought to have 
originated from the soil organism; Kluyvera ascorbata (Humeniuk et al., 2002) and show 
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only approximately 40% homology with the TEM or SHV β-lactamases (Bradford, 2001). 
Over 50 types of these enzymes have now been described and have been classified into five 
families based on phylogenetic studies: CTX-M-1 group consists of six plasmid-mediated 
enzymes: CTX-M-1, CTX-M-3, CTX-M-10, CTX-M-12, CTX-M-15 and FEC-1 including 
some unpublished enzymes. CTX-M-2 group consists of eight plasmid-mediated enzymes 
viz; CTX-M-2, CTX-M-4, CTX-M-4L, CTX-M-5, CTX-M-6, CTX-M-7, CTX-M-20 and 
Toho-1. CTX-M-8 is the sole member of its group. CTX-M-9 group consists of CTX-M-9, 
CTX-M-13, CTX-M-14, CTX-M-16, CTX-M-17, CTX-M-19, CTX-M-21, CTX-M-27 and 
Toho-2. CTX-M-25 group has two members: CTX-M-25 and CTX-M-26 (Bonnet, 2004). 
The serine residue at position 237 is thought to play a role in the extended spectrum 
activity of these β-lactamases. They are also better inhibited by tazobactam than sulbactam 
and clavulanate. The CTX-M β-lactamases have been found in different species of Gram-
negative bacteria worldwide and are now the most common enzymes in community isolates 
(Bush and Fisher, 2011; Peirano et al., 2011). 
 
2.2.5 OXA β-lactamases 
This group of class D β-lactamases are characterised by the ability to hydrolyse cloxacillin 
and oxacillin and are poorly inhibited by clavulanate (Bush et al., 1995). There is only about 
20-30% amino acid homology between the members of the group so the enzymes are quite a 
diverse group in terms of structure (Bradford, 2001). OXA β-lactamases are found mainly in 
P. aeruginosa but have also been described in other Gram-negative bacteria. The ESBL 
variants have one of two amino acid substitutions: asparagine for serine at position 73 or 
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aspartate for glycine at position 157 which may be particularly necessary for high level 
resistance to ceftazidime (Danel et al., 1999). 
 
2.2.6 Laboratory detection of Extended Spectrum beta lactamases 
The laboratory detection of ESBLs in microorganisms can be broadly classified into: (i) 
Phenotypic methods (screening and confirmatory tests) which are based on the ability of the 
ESBLs to hydrolyse third generation cephalosporins and be inhibited by β-lactamase 
inhibitors such as clavulanic acid. (ii) Genotypic methods which employ molecular 
techniques to determine the genes responsible for ESBL production in various organisms. 
The phenotypic tests are easy to do, cost-effective and have been incorporated into several 
automated systems for ESBL detection (Wiegand et al., 2007) but these tests are unable to 
differentiate between the types of ESBL enzymes hence, the need for genotypic tests. The 
molecular methods are also able to detect low levels of enzyme production which may 
otherwise be missed by the phenotypic tests (Woodford and Sundsfjord, 2005). Genotypic 
tests can also be carried out directly on clinical specimens eliminating the need for culturing 
and as a result reducing detection time significantly (Tenover, 2007). These genotypic 
methods are however cost intensive and are not readily available to smaller diagnostic 
laboratories. The screening test involves screening with an indicator cephalosporin which is 
based on resistance or diminished susceptibility of likely ESBL producers to these β-lactams. 
The confirmatory tests are based on synergy demonstrated between the oxymino 
cephalosporins and the β-lactamase inhibitor, clavulanic acid, confirming the production of 
extended spectrum beta-lactamases by those isolates. 
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2.2.6.1 Screening Tests 
The disk diffusion method can be used to screen for the presence of ESBLs by including one 
or more indicator cephalosporins (cefpodoxime, ceftazidime, cefotaxime, aztreonam or 
ceftriaxone) in the antibiotic panel for susceptibility tests. However, because the substrate 
profiles for the ESBLs differ, the Centre for Laboratory Standards Institute (CLSI) (formerly 
NCCLS) recommends the use of more than one cephalosporin to improve the sensitivity of 
detection (NCCLS, 2005). It is sufficient to use ceftazidime which is a consistently good 
substrate for the TEM and SHV variants and cefotaxime which is a substrate for the CTX-M 
enzymes. Cefpodoxime has been reported as the best single indicator drug (if only a single 
drug can be used) (Jarlier et al., 1988) but it can yield a high number of false positive results 
due to other mechanisms of β-lactam resistance (Livermore and Paterson, 2006). Isolates that 
show resistance or diminished susceptibility to any of these agents should be further 
subjected to the confirmatory test. 
 Dilution methods can also be used to screen for ESBL production. Ceftazidime, 
aztreonam, cefotaxime and ceftriaxone are used at a screening concentration of 1µg/ml or 
cefpodoxime at a concentration of 1µg/ml for Proteus mirabilis and 4µg/ml for the others. 
The presence of growth at or above these concentrations is indicative of possible ESBL 
production (NCCLS, 2005). 
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2.2.6.2 Phenotypic confirmatory tests 
2.2.6.2.1 Combination disk tests 
This involves the use of antimicrobial disks containing a cephalosporin with or without 
clavulanate. The test is performed following the same procedures as for normal disc diffusion 
tests on Mueller-Hinton agar plates inoculated with the test organism and incubated for 16-
18h. The zone diameters are then measured and a difference of >5mm between the zone 
diameters of the cephalosporin alone and the combined cephalosporin/clavulanate disk 
phenotypically confirms the production of ESBLs (NCCLS, 2005). 
 
2.2.6.2.2 Broth microdilution 
Broth microdilution tests are carried out according to the standard methods as recommended 
by CLSI using ceftazidime (0.25-128µg/ml), ceftazidime plus clavulanic acid (0.25/4-
128/4µg/ml), cefotaxime (0.25-64µg/ml) or cefotaxime plus clavulanic acid (0.25/4-
64/4µg/ml) (Queenan et al., 2004). A decrease of ≥ 3 twofold serial dilution in minimum 
inhibitory concentration (MIC) of any of the cephalosporins in combination with clavulanic 
acid compared to the MIC of the cephalosporin alone confirms ESBL production (NCCLS, 
2005). 
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2.2.6.2.3 Double disk synergy test (DDST) 
This test is also based on demonstrable synergy between cephalosporins and clavulanic acid 
which is a β-lactamase inhibitor. It was described by Jarlier et al. (1988) and is technically 
easy to perform but requires experienced interpretation. Two to four disks of third generation 
cephalosporins are placed on either side of a centrally placed augmentin 
(amoxicillin+clavulanic acid) disk at a distance of 30mm centre to centre on a Mueller-
Hinton agar plate. An extension of the zone of inhibition of any of the cephalosporins 
towards the augmentin disk confirms ESBL production (Jarlier et al., 1988). 
Several studies have compared the various methods of ESBL detection and have 
reported the sensitivity of DDST as ranging between 79%-97% to 94% - 100% (Vercauteren 
et al., 1997; Randegger et al., 2001). The sensitivity is also low when extended spectrum β-
lactamase activity is very low causing wide zones of inhibition around the cephalosporin and 
aztreonam disks (Revathi and Singh, 1997). False negative results have been reported in 
organisms harbouring SHV-2, SHV-3 or TEM-12 enzymes (Thomson and Sanders, 1992; 
Vercauteren et al., 1997; Ho et al., 1998). False positive results also occur in S. maltophilia 
because aztreonam is not a substrate for the metalloenzymes and clavulanic acid inhibits 
other β-lactamases produced by this organism and not just the ESBLs (Munoz-Bellido and 
Garcia-Rodriguez, 1998). In order to improve sensitivity of the test, some authors have 
reduced the distance between the disks to 20mm in isolates strongly suspected to harbour 
ESBLs but producing negative results (Thomson and Sanders, 1992; Ho et al., 1998; Tzelepi 
et al., 2000) or the distance can also be increased to 40mm in those that produce wide zones 
of inhibition. 
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2.2.6.2.4  Three dimensional test 
The three dimensional test was first described by Thomson and Sanders (1992) and it 
provides evidence of inactivation of extended spectrum cephalosporins or aztreonam by 
ESBLs without the use of β-lactam inhibitors. The surface of a Mueller-Hinton agar plate is 
inoculated as per standard procedure for diffusion susceptibility tests and in addition a 
circular slit is cut in the agar along the axis of the margin. A heavy inoculum of the test 
organism (10
9
 to 10
10
 CFU/ml) is then pipetted into the slit and disks impregnated with the β-
lactams are placed on the surface of the agar 3mm from the slit. Inactivation of the drug due 
to beta lactamase activity is visualised as a distortion of the circular inhibition zone or the 
presence of discrete colonies near the slit (Thompson and Sanders, 1992). This test is 
however, technically challenging to execute though highly sensitive (Bradford, 2001). 
 
2.2.6.2.5  Inhibitor-potentiated disk diffusion tests 
Disks containing ceftazidime, cefotaxime, ceftriaxone and aztreonam are placed 
simultaneously on Mueller-Hinton agar plates supplemented with 4µg/ml clavulanic acid and 
those without clavulanic acid and incubated. A difference of >10mm in the zone diameters in 
the two media denotes a positive result for ESBL production (Ho et al., 1998). The 
clavulanate containing plates, however, need to be freshly prepared as the potency of 
clavulanic acid begins to decrease after 72 hours. 
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2.2.6.2.6  Cephalosporin/Clavulanate combination disks on Iso- 
   sensitest agar 
This is the method recommended by the British Society for Antimicrobial Chemotherapy 
(BSAC) which interprets semi-confluent growth on Iso-sensitest agar using ceftazidime-
clavulanate and cefotaxime-clavulanate combination disks as positive for ESBL production. 
A ratio of cephalosporin/clavulanate size to cephalosporin zone size of 1.5 or more signifies 
ESBL activity. The sensitivity is reported to be 93% for both ceftazidime and cefotaxime 
(M’zali et al., 2000; Deepthi and Deepthi, 2010). 
 
2.2.6.2.7  Disk approximation tests 
A cefoxitin disk is placed at a distance of 2.5cm from the cephalosporin disk and production 
of inducible β-lactamases is indicated by flattening of the zone of inhibition of the 
cephalosporin disk towards the inducer disk by >1mm. There are also commercial methods 
available for ESBL detection (Revathi and Singh, 1997). 
 
2.2.6.2.8  E-Test 
The E-test (AB Biodisk, Solna, Sweden) is based on the MIC method and consists of a test 
strip which carries two gradients on opposite ends. One side contains the third generation 
cephalosporin while the other end carries the cephalosporin/clavulanic acid combination. The 
MIC is taken as the point where the ellipse of inhibition intersects with the E-test strip edge 
and a ratio of cephalosporin MIC to cephalosporin/clavulanic acid MIC ≥8 indicates ESBL 
33 
 
production. The sensitivity of the E-test ranges from 87-100% and specificity from 95-100% 
(Cormican et al., 1996). 
 
2.2.6.2.9 Vitek ESBL test 
This test also makes use of cefotaxime or ceftazidime (0.5µg/ml) alone and in combination 
with clavulanic acid (4µg/ml) for ESBL detection. The Vitek cards (bioMerieux Vitek, 
Hazelton, Missouri) are inoculated as per manufacturer’s instructions and analysis of the 
wells is performed automatically after 4-15h of incubation at a set threshold. A predetermined 
reduction in the growth of wells containing cephalosporins with clavulanic acid compared 
with the wells containing cephalosporin alone indicates the presence of ESBLs (Sanders et 
al., 1996). 
 
2.2.6.2.10  Phoenix Automated Microbiology System (Benton 
 Dickinson Biosciences, Sparks, Md). 
This method has been recommended as a rapid method for ESBL detection. It uses growth 
response to cefpodoxime, ceftazidime, ceftriaxone and cefotaxime with or without clavulanic 
acid to detect ESBL production. Results are usually available within 6 hours (Park et al., 
2007). 
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2.2.6.3  Genotypic detection of ESBLs 
The molecular method most commonly used for ESBL detection is Polymerase chain reaction 
(PCR) amplification of blaTEM, blaSHV and blaCTX-M genes using specific oligonucleotide 
primers and subsequent sequencing of the PCR amplicons. Nucleotide sequencing is the gold 
standard for identification of ESBL genes especially blaTEM and blaSHV. It is necessary to 
differentiate between the non-ESBL parent enzymes (TEM-1, TEM-2, SHV-1) and other 
variants of the ESBL enzymes as point mutations around the active site of the parent enzymes 
have led to amino acid substitutions that have expanded their spectrum of activity (Bradford, 
2001; Al-Jasser, 2006a). 
Other methods that do not require sequencing have been developed and these include: 
PCR with restriction fragment length polymorphism (PCR-RFLP) (Arlet et al., 1995), PCR 
with single strand conformational polymorphism (PCR-SSCP) (M’zali et al., 1998), ligase 
chain reaction (Kim & Lee, 2000), restriction site insertion PCR and real time PCR (RT-
PCR). The applications of these are, however, limited because of the ever-increasing number 
of ESBL subtypes and continuous evolution of the enzymes. Sequencing is also not always 
straightforward because some isolates may carry multiple copies of ESBL genes. 
However, PCR amplification of blaCTX-M gene is often sufficient to conclude that a 
CTX-M enzyme is responsible for the ESBL phenotype. Methods that have been developed 
for rapid screening of isolates for blaCTX-M include PCR assay with four sets of primers to 
amplify group-specific CTX-M genes, amplification of a universal DNA fragment specific 
for the different groups of CTX-M β-lactamases, duplex PCR, multiplex PCR, RT-PCR, 
pyrosequencing and reverse-line hybridisation (Pitout et al., 2004; Pitout and Laupland, 
2008). 
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Molecular techniques play a huge role in the screening, tracking and monitoring of the 
spread of ESBL-producing organisms especially CTX-M enzyme producers in the 
community and hospital settings and it is hoped that the recent developments of more easily 
accessible and cost-effective molecular methods such as microarrays and rapid-cycle 
sequencing will make the detection and identification of these genes possible in real time 
(Pitout and Laupland, 2008). 
 
2.2.6.4  Challenges of ESBL detection  
The increased prevalence of ESBL-producing bacteria in the hospital and community makes 
it imperative to have laboratory testing methods that provide adequate and accurate 
identification of these enzymes especially in clinical isolates. This, however, remains a huge 
challenge as the detection of ESBL-producing organisms is complex due to multiple factors 
which include production of multiple different β-lactamase types by a single bacterial isolate, 
their varying substrate affinities, the production of ESBLs by organisms that constitutively 
produce the AmpC β-lactamase, the confounding factors that modify the expression of the 
enzymes and the inoculum effect (Gniadkowski, 2001; Al-Jasser, 2006a). 
The MIC of extended spectrum cephalosporins rises dramatically as the inoculum size 
increases beyond that used in routine susceptibility testing resulting in false negative results 
when lower inocula are used (Deepthi and Deepthi, 2010). Studies done have showed that 
isolates which appear susceptible at the standard inoculum of 10
5
/ml have highly elevated 
MICs at higher inocula of 10
7
/ml or 10
8
/ml (Jacoby, 1997). The coexistence of both AmpC β-
lactamase and ESBLs in the same organism often results in elevated cephalosporin MICs 
leading to false negative test results for the detection of ESBLs and this may be due to the 
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fact that AmpC type β-lactamases resist inhibition by clavulanate thereby obscuring the 
synergistic effect of clavulanate and cepahalosporins (Deepthi and Deepthi, 2010). 
 
2.2.7 Extended spectrum beta lactamases produced by Stenotrophomonas 
  maltophilia. 
S. maltophilia produces at least two clinically important beta lactamases designated L1 and 
L2 (Krueger et al., 2001). The L1 enzyme is produced by virtually all strains of the organism 
and belongs to the metallo-enzyme family. It is a zinc-dependent carbapenemase (Bush 
Group 3) which is not inhibited by clavulanic acid. It hydrolyses most beta lactam antibiotics 
including the carbapenems (imipenem and meropenem) which confers S. maltophilia with its 
characteristic resistance to this class of drugs. It is, however, unable to hydrolyse aztreonam 
and therefore, aztreonam may serve as a competitive inhibitor of the L1 enzyme (Munoz 
Bellido et al., 1997). The L2 enzyme belongs to Bush group 2e and is a cephalosporinase 
which is inhibited by clavulanic acid. It possesses a serine active site, exists as a dimer in its 
natural state and is most closely related to the TEM beta lactamases. It has the ability to 
hydrolyse third generation cephalosporins and aztreonam (Munoz Bellido et al., 1997; 
Denton and Kerr, 1998). 
Several studies have shown the existence of other beta lactamases produced by S. 
maltophilia. Cullman and Dick (1990) described the presence of six distinct enzymes in 20 
clinical strains and other reports have confirmed the heterogeneity of beta lactamase 
production in S. maltophilia (Paton et al., 1994; Payne et al., 1994). Al Naiemi et al. (2006) 
also described the presence of a CTX-M type beta lactamase in a strain of S. maltophilia 
isolated from the sputum of a neonate. As previously mentioned, the presence of these ESBLs 
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provides the organism with an even more powerful resistance mechanism with serious 
clinical implications and further limited options for therapy. The ESBL genes are often found 
carried on plasmids, chromosomes and transposons accompanied by genes conferring 
resistance to other classes of antibiotics (Jacoby and Munoz-Price, 2005). The ability of these 
genes to be transferred easily poses a serious threat to the community (Wright and Eiland III, 
2008) and this can be compared to the situation with methicillin resistant Staphylococcus 
aureus where the resistance mechanisms were first noted in important nosocomial pathogens 
followed by appearance of different clones in the community (Pitout et al., 2005). 
A study by Kataoka et al. (2003) reports that the beta lactamases produced by S. 
maltophilia have the ability to aid the survival of strains of P. aeruginosa which are normally 
susceptible to imipenem when the two organisms grow together in culture. This further 
highlights the importance of studying the beta-lactamase enzymes produced by this organism 
in the environment. 
 
2.3 TRIMETHOPRIM-SULFAMETHOXAZOLE 
Trimethoprim-sulfamethoxazole (TMP-SMX), a fixed combination of two antimicrobials was 
first introduced in 1968 following the recognition of several advantages of the two drugs in 
combination over the use of each one individually (Kielhofner, 1990; Eliopoulous and 
Huovinen, 2001; Masters et al., 2003). Trimethoprim is a diaminopyrimidine, a structural 
analog of the pteridine portion of dihydrofolic acid while sulfamethoxazole is a sulfonamide, 
a structural analog of para-aminobenzoic acid (PABA) (Rubin and Swartz 1980, Masters et 
al., 2003). The antibiotic is available for use in a fixed drug ratio of one part TMP to five 
parts SMX (Rubin and Swartz, 1980). 
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2.3.1 Mechanism of action 
Bacteria are obligate folic acid synthesizers and both TMP and SMX inhibit the synthesis of 
tetrahydrofolic acid thereby preventing the production of thymidines, purines and bacterial 
DNA effectively leading to a disruption of bacterial replication (Masters et al., 2003). 
Sulfamethoxazole blocks the synthesis dihydrofolic acid from para-aminobenzoic acid by 
inhibiting dihydropteorate synthetase while in the subsequent step trimethoprim prevents the 
formation of tetrahydrofolic acid from dihydrofolic acid by inhibiting the action of 
dihydrofolic acid reductase. This sequential blockade of two enzymes in the same crucial 
pathway is efficiently bactericidal (Eliopoulos and Huovinen, 2001; Masters et al., 2003). It 
was also hoped that the use of these two drugs in one combination would prevent the 
development of bacterial resistance to any of the individual components alone (Masters et al., 
2003). 
 
2.3.2 Resistance to TMP-SMX 
Resistance of bacteria to TMP-SMX is thought to be mediated by five main mechanisms: the 
development of permeability barriers and/or efflux pumps, naturally unresponsive target 
enzymes, regulational changes in the target enzymes, mutations or recombinational changes 
in the target enzymes and acquired resistance by drug-resistant target enzymes (Eliopoulos 
and Huovinen, 2001). Resistance can also be plasmid or transposon-mediated, particularly the 
plasmid-mediated production of TMP-resistant forms of dihydrofolate reductase (Kielhofner, 
1990; Masters et al., 2003). 
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2.4 THE FLUOROQUINOLONES 
The fluoroquinolones are a group of synthetic antimicrobial agents whose origins lie in the 
use of chloroquine for the treatment of malaria. During the commercial production of 
chloroquine, a by-product found to have antibacterial activity was isolated and modified to 
produce the first quinolone, nalidixic acid (Appelbaum and Hunter, 2000; Anderson and 
McGowan, 2003; Enami et al., 2005). The use of nalidixic acid was, however, limited due to 
the need for frequent administration, a high tendency to select for resistant Gram-negative 
bacilli, poor activity against Gram-positive bacteria, photosensitivity reactions in patients and 
the potential to cause convulsions in patients with seizure disorders (Zhanel et al., 1999). 
Since then, several modifications to the basic structure have led to the development of 
new members of the class which have evolved from compounds with limited spectrum to the 
newer agents with remarkable broad spectrum activity (Anderson and McGowan, 2003; 
Bolon, 2009; Sharma et al., 2009). The fluoroquinolones have become the only synthetic 
drugs to rival the β-lactams in terms of impact in clinical usage. This increased usage has 
been attributed to their rapid bactericidal effect against most organisms that are susceptible 
which is of growing importance clinically because of the increasing number of patients who 
are critically ill or immunosuppressed. The fluoroquinolones also penetrate tissues and 
mammalian cells effectively; important when the offending organisms are intracellular 
(Appelbaum and Hunter, 2000). 
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2.4.1 Structure of Quinolones 
All members of the quinolone group possess one of two types of ring structures: a 
naphythyridone nucleus which has nitrogen at position 1 and 8 or a quinolone nucleus with 
only nitrogen at position 1. They also have an exo-cyclic oxygen and carboxylic acid side 
chain at position 3 (Appelbaum and Hunter, 2000). Most of the new fluoroquinolones are 
analogs of the basic quinolone nucleus with important structural modifications occurring at 
positions 1, 5, 7 and 8 leading to differences between the various agents (Zhanel et al., 1999; 
Enami et al., 2005; Sharma et al., 2009). 
 
2.4.2 Classification of fluoroquinolones 
Fluoroquinolones can be classified into four generations based on their activity against 
microorganisms. The first generation fluoroquinolones include nalidixic acid and cinoxin 
which have moderate Gram-negative activity and are no longer commonly used in the 
treatment of infections because frequent dosing is required and bacteria easily acquire 
resistance to these agents (King et al., 2000). Lomefloxacin, norfloxacin, enoxacin, ofloxacin 
and ciprofloxacin are the second generation fluoroquinolones which have improved Gram-
negative coverage as well as some Gram-positive and atypical pathogen coverage. These 
drugs have wider clinical application than their first generation counterparts (King et al., 
2000; Oliphant and Green, 2002). 
The newer fluoroquinolones are, therefore, those of the third and fourth generation 
which include levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin and trovafloxacin. They 
retain the improved Gram-negative coverage of the second generation drugs but also have 
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improved Gram-positive activity particularly against penicillin-susceptible and penicillin-
resistant Streptococcus pneumoniae and atypical pathogens such as Mycoplasma pneumoniae 
(King et al., 2000). The fourth generation drug trovafloxacin differs only in the fact that it 
also covers anaerobic organisms and has an even more improved Gram-positive coverage 
(Oliphant and Green, 2002) 
 
2.4.3 Mechanism of action 
The fluoroquinolones act by inhibiting the bacterial DNA gyrase and topoisomerase IV 
enzymes which are involved in bacterial DNA synthesis thereby enabling the drugs to be both 
specific and bactericidal (Blondeau, 2004; Bolon, 2009; Sharma et al., 2009). DNA gyrase 
inserts negative superhelical twists in the double helix of bacterial DNA ahead of the 
replication fork thereby aiding the separation of daughter chromosomes. This is crucial for 
the initiation of DNA replication and the binding of initiation proteins. It is a type II 
topoisomerase composed of two GyrA and two GyrB monomeric subunits which are encoded 
by the gyrA and gyrB genes (Hooper, 1995; Blondeau, 2004).  It has been proposed that the 
fluoroquinolones bind to the DNA binding groove between the A and B subunits leading to 
conformational changes to DNA gyrase molecule (Hooper, 1995). 
The second target for the fluoroquinolones is the topoisomerase IV enzyme. 
Topoisomerase IV is responsible for decatenation which refers to the removing of the 
interlinking daughter chromosomes thereby allowing separation into two daughter cells at the 
end of a round of replication (Kato et al., 1990). It consists of four homologous monomeric 
subunits, two ParC and two ParE subunits which are encoded by the parC and pare genes 
respectively. The fluoroquinolones interact with the enzyme bound DNA complex to create 
42 
 
conformational changes that result in the inhibition of normal enzyme activity. Consequently, 
the new drug-enzyme-DNA complex blocks progression of the replication fork, thereby 
inhibiting normal bacterial DNA synthesis and resulting ultimately in rapid bacterial cell 
death (Blondeau, 2004). 
 
2.4.4 Advantages of the newer fluoroquinolones 
Unlike the earlier quinolones that required frequent dosing and had several unwanted side 
effects, the newer agents display a high bioavailability, low protein binding and longer 
elimination half-lives (Applebaum and Hunter, 2000). Once daily administration also 
significantly increases patient compliance. Resistance to fluoroquinolones can arise from 
mutations or alterations in the target sites; DNA gyrase and topoisomerase IV and mutations 
affecting the accumulation of the drugs in the bacteria such as variations in the uptake reflux 
system (Applebaum and Hunter, 2000; Emmerson and Jones, 2003; Sharma et al., 2009). 
Data from studies on resistant mutant strains suggests that the newer generation 
fluoroquinolones may have a dual binding mechanism of action inhibiting both DNA gyrase 
and topoisomerase IV and owing to the rarity of double mutations, the preferential use of the 
newer drugs could potentially limit the emergence of fluoroquinolones resistance (Blondeau, 
2004). 
Several studies have reported the in vitro activity of the newer fluoroquinolones 
compared with older fluoroquinolones against S. maltophilia (Sanchez-Hernandez et al., 
1999; Munoz-Bellido et al., 2000; Weiss et al., 2000; Ribera et al, 2002). The study of 
Valdezate et al. (1999) reported that the minimum inhibitory concentrations of the newer 
fluoroquinolones were eight fold lower than those for ofloxacin and ciprofloxacin as well as 
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16-128 fold lower than those of perfloxacin, norfloxacin and nalidixic acid. The 
fluoroquinolones may also provide the option of choice for patients who are intolerant to the 
sulphur content of sulphamethoxazole. 
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CHAPTER THREE 
ANTIBIOGRAM CHARACTERISTICS OF COMMENSAL Stenotrophomonas 
maltophilia ISOLATED FROM NKONKOBE MUNICIPALITY ENVIRONMENT IN 
THE EASTERN CAPE 
3.0 ABSTRACT 
Stenotrophomonas maltophilia has become an increasingly important nosocomial and 
opportunistic pathogen worldwide. Trimethoprim-sulphamethoxazole (TMP-SMX) is the 
recommended treatment for S. maltophilia infections but its effect is only bacteriostatic and 
resistance to the drug is being reported, hence the need for effective alternative treatment 
options. The fluoroquinolones have been proposed as a possible alternative and have shown 
good activity in vitro. This study reports the antimicrobial susceptibility profile of S. 
maltophilia obtained from plants rhizosphere in Nkonkobe municipality environment of 
Eastern Cape Pronvince of South Africa. 110 isolates were examined of which 63.38% were 
susceptible to TMP-SMX. The new fluoroquinolones, levofloxacin, gatifloxacin and 
moxifloxacin all showed good activity with susceptibilities of 94.7%, 92.3% and 88% 
respectively. Ciprofloxacin was the least effective fluoroquinolone with susceptibility of 
75.9%. Resistance to the fluoroquinolones ranged from 1.3 - 2.7%. All TMP-SMX resistant 
isolates were susceptible to four or five of the fluoroquinolones. The new fluoroquinolones 
provide a possible alternative for the treatment of TMP-SMX resistant S. maltophilia 
infection in the Eastern Cape environment, but further studies are necessary in order to 
determine their effects in vivo. 
Keywords: Stenotrophomonas maltophilia, trimethoprim-sulphamethoxazole resistance, 
fluoroquinolones, commensal.   
45 
 
3.1 INTRODUCTION 
Stenotrophomonas maltophilia, a non-fermentative Gram-negative bacillus, which was 
initially thought to be a predominantly non-pathogenic environmental organism, is becoming 
progressively recognised as an important nosocomial organism responsible for significant 
morbidity and mortality in immunocompromised and debilitated patients (Denton and Kerr, 
1998; Valdezate et al., 2001; Hu et al., 2011). The increase in S. maltophilia infections has 
been attributed to advances in cancer treatment, the use of invasive therapeutic devices and 
the widespread use of broad spectrum antibiotics (Denton and Kerr, 1998; Koseoglu et al., 
2004; Al-Jasser, 2006a; Falgas et al., 2008) and potential risk factors for infection include 
chronic respiratory disorders (particulary cystic fibrosis), presence of an indwelling catether, 
prolonged endotracheal intubation, malignancies, previous exposure to antibiotics and 
prolonged hospitalisation (Hu et al., 2011). It has been implicated in several forms of 
infections including bacteremia, wound infections, skin infections, pulmonary infections, 
urinary tract infections, endocarditis and meningitis but treatment poses an immense 
challenge for clinicians as the bacteria is highly resistant to several classes of antibiotics 
further limiting treatment options (Alonso et al., 2000). 
S. maltophilia displays a vast array of resistance mechanisms which contribute 
independently or collectively to its multi-drug resistant status (Toleman et al., 2007). These 
include the expression of multiple β-lactamases, inducible efflux pumps, outer membrane 
impermeability (Valdezate et al., 2001) and also the acquisition of integrons, plasmids and 
transposons which carry various resistance genes (Hu et al., 2011). It does not, however, 
show mutations in the quinolone-resistance determining regions (Toleman et al., 2007) 
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Trimethoprim-sulfamethoxazole (TMP-SMX) has been recommended as the 
treatment of choice for S. maltophilia infections based on results of in vitro susceptibility 
testing confirming effectiveness and favourable clinical outcomes observed in patients treated 
with this drug (Denton and Kerr, 1998; Berg et al., 1999; Betriu et al., 2002; Gales et al., 
2001; Krueger et al., 2001). However, the effect of the drug is only bacteriostatic and it is not 
convenient to use in severely ill patients especially those who have polymicrobial infections 
that need complicated antibiotic regimens (Weiss et al., 2000). Furthermore, strains resistant 
to this drug have been reported although the mechanism of resistance is not well understood 
(Vartivarian et al., 1994; Chang et al., 2007; Nicodemo and Paez, 2007; Hu et al., 2011). 
There are also issues relating to allergic reactions from the use of TMP-SMX due to the 
accumulation of the nitroso metabolite of sulphamethoxazole leading to the formation of 
sulphamethoxazole-specific antibodies as well as gluthathione and ascorbic acid deficiency 
(Cheng et al., 2008; Falgas et al., 2008).  
Several studies have proposed that the new quinolones could be an alternative 
therapeutic option for the treatment of infections caused by this organism (Weiss et al., 2000; 
Valdezate et al., 2001; Giamarellos-Bourboulis et al., 2002; Nicodemo et al., 2004). This 
study was thus carried out in order to determine the antibiotic susceptibility profile of 
Stenotrophomonas maltophilia isolates in the Eastern Cape environment and compare the 
effects of the newer fluoroquinolones and TMP-SMX on these isolates. 
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3.2 MATERIALS AND METHODS 
3.2.1 Source of Isolates 
One hundred and ten (110) S. maltophilia isolates were obtained from the culture collection 
of the Applied and Environmental Microbiology Research Group (AEMREG), University of 
Fort Hare for use in this study. The bacteria had been previously isolated from the 
rhizosphere of plants in the Eastern Cape environment and identified using standard 
biochemical methods and confirmed using the API 20NE identification kit. The isolates were 
then confirmed up to species level using species specific PCR and stored at -20
o
C. 
 
3.2.2 Antibiotic susceptibility tests 
The antibiogram characteristics of the isolates was determined according to the Kirby-Bauer 
method for disc diffusion susceptibility testing following the CLSI (formerly NCCLS) 
(NCCLS, 2005) standardized guidelines for susceptibility testing using commercial antibiotic 
discs. A total of 21 antibiotic discs (MAST Diagnostics, Merseyside, United Kingdom) were 
used which include: meropenem (30µg), ampicillin (10µg), ampicillin-sulbactam (30µg), 
cefuroxime (30µg), aztreonam (30µg), trimethoprim-sulphamethoxazole (1.25µg+23.75µg), 
trimethoprim (5µg), minocycline (30µg), kanamycin (30µg), ofloxacin (5µg), ciprofloxacin 
(5µg), levofloxacin (5µg), gatifloxacin (5µg), moxifloxacin (5µg), ceftazidime (30µg), 
cefpodoxime (10µg), cefepime (30µg), cefotaxime (30µg), augmentin (30µg), colistin 
sulphate (10µg) and polymyxin B (300U). 
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3.2.3 Preparation of McFarland Standard 
Exactly 0.5 ml of 0.048 M BaCl2 (1.17% w/v BaCl2.2H2O) was added to 99.5 ml of 0.18 M 
H2SO4 (1% w/v) while constantly stirring. The suspension was thoroughly mixed to ensure 
that it is even and then using a 1cm light path, a matched cuvette and water as a blank 
standard, the absorbance was measured in a spectrophotometer at a wavelength of 625nm. 
The acceptable absorbance range for the standard is 0.08 – 0.13. The standard was then stored 
in tubes of the same size and volume as those that were used in standardizing the inoculums 
and stored at room temperature away from light. 
 
3.2.4 Standardization of inocula 
The stock cultures were re-activated by subculturing into tubes containing nutrient broth and 
incubated for 24h at 37
o
C with shaking. The organisms were further subcultured onto nutrient 
agar plates prepared according to manufacturer’s instructions and again incubated for 24h at 
37
o
C. Three to five colonies from each plate were then suspended in tubes containing 5ml of 
sterile distilled water and vortexed thoroughly to achieve a uniform suspension. The turbidity 
of the suspension was compared to that of the 0.5 McFarland standard and adjusted as 
required. The standardized inocula were used in the antibiotic susceptibility tests within 15 
minutes (NCCLS, 2005). 
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3.2.5 Inoculation of plates 
Freshly prepared Mueller-Hinton agar plates were inoculated with the bacterial suspension 
using a sterile swab. The plates were carefully streaked all over in three directions to ensure 
uniform growth. Antibiotic discs were then applied to the surface of the agar using sterile 
forceps and the plates incubated at 35
o
C for 18-24h. The zones of inhibition were then 
measured using a ruler and interpreted using available interpretive charts. S. maltophilia 
DSM 50170 was used as a control strain. 
 
3.3 RESULTS 
The antibiogram profile of the Stenotrophomonas maltophilia isolates tested is as shown in 
the Table 3.1. The antibiogram results showed that only 63.4% of the isolates were 
susceptible to trimethoprim-sulfamethoxazole. Susceptibility to the fluoroquinolones, 
however, ranged from 80% to 94.7% with levofloxacin showing the highest susceptibility and 
ciprofloxacin being the least effective of the fluoroquinolones. Resistance ranged between 
1.3% and 2.7%. Isolates also showed high susceptibility to the polymyxins, colistin sulphate 
and polymyxin B, with both having 97.2% susceptibility rates. 
Susceptibility to the cephalosporins was variable with ceftazidime being the most 
effective with 81.8% of the isolates being susceptible to the drug. The isolates were, however, 
highly resistant to cefotaxime and particularly cefpodoxime with 81.6% and 98.7% resistance 
respectively. Despite S. maltophilia isolates being inherently resistant to the carbapenems, 
87.3% of the isolates in this study showed zone diameters within the susceptible range for 
meropenem according to the interpretive charts. Resistance to trimethoprim and cefuroxime 
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was 94.4% and 95.8% respectively. All the isolates that were interpreted as resistant or 
intermediate to TMP-SMX were susceptible to the fluoroquinolones tested. However, four of 
the isolates only showed intermediate susceptibility to ciprofloxacin and all were susceptible 
to the remaining fluoroquinolones. 
 The multiple antibiotic resistance (MAR) index, when applied to a single isolate, is 
defined as [a/b], where [a] represents the number of antibiotics to which the isolates was 
resistant and [b] represent the number of antibiotics against which the isolate was tested. 
MAR index higher than 0.2 identifies organisms that originate from high-risk sources of 
contamination, where antibiotics are often used (Krumperman, 1983). The S. maltophilia 
isolates in this study showed multiple drug resistance to between one and up to thirteen 
antibiotics in the panel tested with the MAR indices ranging from 0.06 to 0.62 (Fig 3.1). Over 
80% of the isolates had an MAR index greater than 0.2 and about 1% of the isolates were 
resistant to thirteen of the twenty-one antibiotics tested resulting in an MAR index of 0.7. 
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Table 3.1: Antibiogram of the commensal Stenotrophomonas maltophilia. 
ANTIBIOTICS 
SUSCEPTIBLE 
(%) 
INTERMEDIATE 
(%) 
RESISTANT 
(%) 
Meropenem 87.3 3.8 8.9 
Ampicillin 42.6 1.5 55.9 
Minocycline 93.7 0 6.3 
Kanamycin 40.6 7.2 52.2 
Ofloxacin 89.2 8.1 2.7 
Ciprofloxacin 76.0 21.5 2.5 
Levofloxacin 94.7 4.0 1.3 
Moxifloxacin 88.0 9.3 2.7 
Gatifloxacin 92.3 6.4 1.3 
Ceftazidime 81.8 5.2 13.0 
Cefpodoxime 0 1.3 98.7 
Cefepime 58.4 10.4 31.2 
Cefotaxime 5.2 13.2 81.6 
Augmentin 59.7 7.8 32.5 
Colistin sulphate 97.2 0 2.8 
Polymyxin B 97.2 0 2.8 
Trimethoprim-
sulfamethoxazole 
63.4 8.4 28.2 
Cefuroxime 2.8 2.8 94.4 
Trimethoprim 2.8 1.4 95.8 
Aztreonam 14.3 27.1 58.6 
Ampicillin-sulbactam 73.0 4.0 23.0 
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Fig 3.1: Multiple Antibiotic Resistant Index (MARI) of Stenotrophomonas maltophilia. 
 
3.4 DISCUSSION 
S. maltophilia is characterised by resistance to different classes of antibiotics. 
Generally, in this study which was in agreement with most other studies that have 
investigated the antimicrobial susceptibility profile of this organism, isolates tested were 
inherently resistant to several antibiotic groups including β-lactams, macrolides and 
aminoglycosides (Valdezate et al., 2001). Interestingly though, the results show that 87.3% of 
the isolates tested were susceptible to meropenem but these isolates cannot be considered 
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truly susceptible because resistant stable mutants are easily and quickly selected when S. 
maltophilia isolates are exposed to carbapenems rendering the drugs ineffective against them 
(Howe et al., 1997). 
Trimethoprim-sulfamethoxazole (TMP-SMX) is generally accepted worldwide as the 
antibiotic of choice for the treatment of infections caused by this organism. Numerous studies 
have found the antibiotic to be the most effective amongst those tested (Tripodi et al., 2001; 
Betriu et al., 2002; Al-Jasser, 2006b) and in this study, 63.4% of the isolates tested were 
susceptible to the drug while resistance was observed in 28.2%. This is similar to the results 
obtained by Hu et al. (2011) in their study in which 66.7% of the 102 isolates tested were 
susceptible to TMP-SMX while 30.4% of them were resistant. This was attributed to the 
selection pressure caused by extensive use of the drug in these isolates which were mainly 
from patients with serious debilitating diseases and poor immunity. Chang et al. (2007) also 
reported a resistance rate of 25% to TMP/SMX and Valdezate et al. (2001) in their study of 
unique Stenotrophomonas maltophilia strains reported a resistance of 26.2%. These values 
are significantly higher than the reported worldwide resistance rates of less than 10%. Results 
from the SENTRY study (Gales et al., 2001) encompassing data from Europe, Latin America 
and North America indicates that the level of resistance to TMP-SMX ranges from 2% to 
10% depending on location and therefore Valdezate et al. (2001) suggest that these 
differences may be due to the use of different methodologies and varying breakpoints. 
The presence of TMP-SMX-resistant S. maltophilia strains has significant 
implications. A study by Tsiodras et al. (2000) investigated the clinical implications of 
TMP/SMX resistant strains and found that these infections occurred in severely ill patients 
with extensive exposure to the health care system and often required invasive procedures 
such as surgery or catheter removal for effective treatment. Infections were directly 
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associated with severe morbidity but exposure to appropriate therapy tended to be protective 
against death. 
It has been suggested that newer fluoroquinolones may be a suitable alternative 
treatment option for S. maltophilia infections. In agreement with other studies (Biedenbach et 
al., 1999; Vartivarian et al., 1994; Valdezate et al., 1999; Weiss et al., 2000; Valdezate et al., 
2001; Giamarellos-Bourboulis et al., 2002), the new fluoroquinolones, levofloxacin, 
gatifloxacin and moxifloxacin all showed good activity against the isolates in the present 
study with susceptibility ranging from 88% to 94.67% whereas the susceptibility to 
ciprofloxacin was 76%. Valdezate et al. (1999) reported that more than 95% of the isolates 
tested in their study were susceptible to the newer fluoroquinolones and Weiss et al. (2000) in 
a comparison of seven quinolones found that clinafloxacin, moxifloxacin and trovafloxacin 
had significantly better in vitro activity compared to ciprofloxacin and levofloxacin. 
Quinolones were also effective against some of the isolates that were resistant to TMP-SMX. 
This is comparable to the results in this study in which all the TMP-SMX-resistant isolates 
were susceptible to the fluoroquinolones tested except for four TMP-SMX-resistant isolates 
that showed only intermediate susceptibility to ciprofloxacin. Giamarellos-Bourboulis et al. 
(2002) also reported that moxifloxacin was bactericidal against genetically distinct S. 
maltophilia isolates that were resistant to TMP-SMX. Furthermore, the newer 
fluoroquinolones can reach a concentration that is at least five times their serum 
concentration in the lungs (Zhanel et al., 1999) and since they exert concentration-dependent 
killing, the fluoroquinolones provide an option for the treatment of respiratory tract infections 
caused by S. maltophilia particularly in patients with cystic fibrosis (Weiss et al., 2000). 
More than 80% of the S. maltophilia isolates in this study showed a MAR index >0.2. 
This infers that these isolates originated from an environment that has been contaminated 
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through the use of antibiotics. MAR indexing may allow the possibility of distinguishing the 
source of contamination leading to the development of multiple antibiotic resistances in these 
organisms (Krumperman, 1998). The Eastern Cape Province is a rural environment with large 
agriculture and livestock-rearing concerns. These multi-drug resistant isolates may have 
emerged as a result of high selective pressure in the environment due to sub-optimal use of 
antibiotics but this remains to be determined.  
Recent studies done have indicated that resistance genes responsible for TMP-SMX 
resistance are linked to insertion sequence common region (ISCR) elements which are DNA 
sequences found beyond and close to the 3’ conserved sequences of class 1 integrons (Chang 
et al., 2007). These ISCR elements have been identified in numerous Gram-negative bacteria 
and are thought to be responsible for the mobility and dissemination of many antibiotic 
resistance genes including extended spectrum β-lactamases, carbapenemase genes and 
aminoglycoside, chloramphenicol and quinolone genes (Avison et al., 2002; Barbolla et al., 
2004; Li and Nikaido, 2004; Toleman et al., 2007).  In this study, all the isolates resistant to 
TMP-SMX showed a high level of resistance to the penicillins, cephalosporins, and the 
aminoglycoside tested, further confirming the multi-drug resistant phenotype of these 
isolates. 
Majority of the studies done to evaluate the antimicrobial susceptibility profile of S. 
maltophilia have been carried out on clinical isolates and no further information is available 
on the antimicrobial susceptibilities of environmental isolates in South Africa. With mounting 
evidence on the interactions between human pathogenic/commensal bacteria and 
environmental bacteria (Seveno et al., 2002; Martinez, 2008; Canton, 2009), the need for 
surveillance of these resistance reservoirs cannot be underestimated. 
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3.5 CONCLUSION 
This study clearly shows the multidrug resistant nature of even commensal S. 
maltophilia and provides insight into the susceptibility profile of this organism in the Eastern 
Cape environment. With all the evidence that suggests that there is interaction between 
commensal organisms and pathogenic bacteria, this information may provide relevant 
information for empirical therapy should these organisms become implicated in clinical 
infections. TMP-SMX remains an effective drug for the treatment of S. maltophilia infections 
but with the increase in resistance among environmental strains of this organism, it is 
important to consider alternative, effective treatment options. The new fluoroquinolones 
provide such an option and further studies are required to determine their therapeutic 
effectiveness in vivo. With continued advances in the field of medicine and improved access 
to healthcare, the problem with nosocomial and opportunistic pathogens such as S. 
maltophilia is not going to go away and it is important that clinicians and microbiologists are 
aware of the resistance phenotypes of these organisms and keep a tight rein of surveillance on 
antibiotic use so that our treatment options do not continue to dwindle; while stepping up 
research on the development of new antimicrobial agents. 
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CHAPTER FOUR 
CTX-M ESBLS IN Stenotrophomonas maltophilia ISOLATES FROM THE EASTERN 
CAPE PROVINCE ENVIRONMENT 
4.0 ABSTRACT 
Resistance of Gram-negative organisms to β-lactam antibiotics is predominantly mediated by 
the production of chromosomal, induced or acquired β-lactamases. Based on the double disc 
synergy tests (DDST), 59.5% of the Stenotrophomonas maltophilia in this study were 
phenotypically confirmed to be producers of extended spectrum β-lactamases (ESBLs). 
Cefepime was the most sensitive indicator cephalosporin with 77% sensitivity. Nine different 
ESBL phenotypes were observed. PCR amplification of the bla genes revealed the presence 
of CTX-M ESBLs belonging to CTX-M-1 group and CTX-M-8 group. The presence of 
ESBLs in these commensal organisms is significant because of the possibility of the spread of 
these genes in the environment and community and the implications of transfer to other 
pathogenic organisms. 
Keywords: Stenotrophomonas maltophilia, extended spectrum beta lactamase (ESBL), CTX-
M group 
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4.1 INTRODUCTION 
β-lactamases remain the leading cause of resistance to the β-lactam group of 
antibiotics among Gram-negative bacteria and the prevalence and incidence of these enzymes 
have been increasing worldwide (Bradford, 2001; Bonnet, 2004; Al-Jasser, 2006a; Deepthi 
and Deepthi, 2010). β-lactamases are found in a wide variety of organisms and most Gram-
negative organisms are thought to possess a chromosomal β-lactamase or acquire these from 
plasmids and transposons in other organisms (Deepthi and Deepthi, 2010). These β-
lactamases have been extensively studied and are divided into four classes: A through D 
based on differences in their amino acid sequences according to Ambler et al. (1991). The 
spread of these enzymes and increasing resistance to β-lactam antibiotics led to the 
development of the oxymino-cephalosporins which were less susceptible to inactivation by 
the β-lactamases (Livermore and Hawkey, 2005). Increased use of these new agents, 
however, has led to the rapid emergence of resistant strains which produced extended 
spectrum β-lactamases (ESBLs) (Bradford, 2001; Paterson and Bonomo, 2005). 
The ESBLs are a rapidly evolving group which belong predominantly to class A and 
D in the Ambler structural classification but the functional classification by Bush et al. 
(1995) clusters them in group 2be. The enzymes hydrolyse the extended-spectrum 
cephalosporins and the monobactams and are generally susceptible to β-lactamase inhibitors 
such as clavulanate, sulbactam and tazobactam. The CTX-M ESBLs are a subgroup of this 
class of ESBLs. 
S. maltophilia produces two inducible β-lactamases designated L1 and L2 which 
mediate its natural resistance to the β-lactam group of antibiotics. L1 is a metallo-enzyme, a 
Zn+-dependent carbapenemase belonging to Bush group 3 and hydrolyses most penicillins, 
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cephalosporins, carbapenems but not monobactams. It is not inhibited by clavulanic acid. The 
L2 β-lactamase is a serine β-lactamase belonging to Bush group 2be. It hydrolyses the 
cephalosporins and the monobactams and is inhibited by clavulanic acid and other β-
lactamase inhibitors. However, several studies have reported the heterogeneity of β-lactamase 
production in S. maltophilia. Payne et al. (1994) reported the presence of seven metallo-
enzymes and eight serine β-lactamases in clinical isolates investigated while Paton et al. 
(1994) reported one metallo-enzyme and three serine β-lactamases. More recently, Al-Naeimi 
et al. (2006) and Lavigne et al. (2008) using phenotypic and genotypic methods were able to 
identify ESBLs belonging to the CTX-M group in clinical isolates of S. maltophilia. These 
are the first reports confirming ESBL production in this nosocomial organism. The purpose 
of this study was to identify, using phenotypic and molecular methods, the prevalence of 
ESBL-producing environmental isolates of S. maltophilia in the Eastern Cape Province. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Phenotypic detection of extended spectrum beta lactamases 
Isolates that showed resistance or intermediate susceptibility to the indicator cephalosporins 
(ceftazidime 30µg, cefotaxime 30µg, cefepime 30µg and cefpodoxime 10µg) in the 
susceptibility tests previously reported (Section 3.3) were subjected to the phenotypic 
confirmatory tests using the double disc synergy test (DDST) as described by Jarlier et al. 
(1988) with modifications. The inoculum was standardized as previously described (NCCLS, 
2005) and streaked on freshly prepared Mueller-Hinton agar plates. Antibiotic discs (MAST 
Diagnostics, Merseyside, United Kingdom) containing ceftazidime (30µg), cefotaxime 
(30µg), cefpodoxime (10µg) and cefepime (30µg) were placed around a central amoxicillin-
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clavulanic acid (30µg) disc at a distance of 25mm centre to centre. Isolates that showed 
synergy towards the central clavulanate disc were phenotypically confirmed to be ESBL 
producers. 
 
4.2.2 Extraction of genomic DNA 
Genomic DNA was extracted using the method of Alzahrani et al. (2010) with modifications. 
The S. maltophilia isolates were subcultured on Luria-Bertani agar plates and incubated at 
37
o
C overnight. Three to five colonies of the bacteria was then suspended in 250 µl of sterile 
nuclease-free water in sterile eppendorf tubes and vortexed to achieve a uniform suspension. 
The cells were then lysed by heating to 100
o
C for 15 min on a heating block (Accublock 
Digital Dry Bath, Labnet). The suspension was then centrifuged (Thermo scientific, Haraeus 
Fresco 17) at 15,000 rpm for 15 min at 4
o
C to remove cell debris and the lysate was stored at 
-20
o
C until used for the PCR reactions. 
 
4.2.3 PCR amplification 
Conventional Polymerase chain reaction (PCR) was used to amplify possible extended 
spectrum β-lactamase genes from the isolates that showed DDST positivity. PCR 
amplification was carried out with specific primers based on already published sequences of 
the ESBL enzyme groups (Table 4.1) as described in the method by Schlesinger et al. (2005) 
with modifications to screen for blaTEM, blaSHV, blaCTX-M, blaIBC, blaPER, blaOXA, blaVEB and 
blaSFO genes. All reactions were performed at a final volume of 25 µl containing 12.5 µl PCR 
master mix 2x (Fermentas), 0.5 µl of each primer (Inqaba Biotec), 3 µl template DNA and 
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8.5 µl nuclease free water (Fermentas) under the following conditions in a Biorad Mycycler 
Thermal Cycler: 15 min at 95
o
C, 35 cycles of 1 min at 94
o
C, 1 min at the annealing 
temperature published for each primer set, 1 min at 72
o
C followed by a further extension for 
10 min at 72
o
C. Ten microlitres of each PCR amplicon was then loaded on 1.5% agarose 
(Pronadisa, low grade EEE agarose) gel containing 0.5x TBE buffer along with 100 bp DNA 
ladder (Fermentas, GeneRuler, 0.5 µg/µl). Electrophoresis was carried out at a voltage of 100 
V for 75 min. The gel was stained with 0.5 µg/ml ethidium bromide and the DNA was then 
visualised with an ultraviolet transilluminator and captured with the documentation software 
Alliance 4.7 (Uvitec). 
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Table 4.1: Primer sequences, annealing temperature, expected product size and 
references. 
Primer 
type and 
gene 
family 
Sequence  Anne
aling 
temp 
(
o
C) 
Reference or 
source 
PCR 
produ
ct size 
(kb) 
TEM F:5’-TCAACATTTCCGTGTCG-3’ 
R:5’-CTGACAGTTACCAATGCTTA-3’ 
42 Schlesinger 
et al., 2005 
0.86 
SHV F:5’-ATGCGTTATATTCGCCTGTG-3’ 
R:5’-AGATAAATCACCACAATGCGC-3’ 
47 Schlesinger 
et al., 2005 
0.78 
CTX-M 1 F:5’-GACGATGTCACTGGCTGAGC-3’  
R:5’-AGCCGCCGACGCTAATACA-3’  
53 Pitout et al. 
(2004)  
0.49 
CTX-M 2 F:5’-ATGATGACTCAGAGCATTCG-3’ 
R:5’-TGGGTTACGATTTTCGCCGC-3’  
55 Saladin et al. 
(2002)  
0.87 
CTX-M 8 F:5’-CTGGAGAAAAGCAGCGGGGG-3’ 
R:5’-ACCCACGATGTGGGTAGCCC-3’  
51 Minarini et 
al. (2007)  
0.58 
CTX-M 9 F:5’-ATGGTGACAAAGAGAGTGCA-3’ 
R:5’-CCCTTCGGCGATGATTCTC-3’  
55 Pitout et al. 
(2004)  
0.87 
OXA F:5’-ACACAATACATATCAACTTCGC-3’  
R:5’-AGTGTGTTTAGAATGGTGATC-3’  
42 Schwaber et 
al. (2005)  
0.81 
IBC F:5’-GGGCGTACAAAGATAATTTCC-3’ 
R:5’-GAAGCAACGTCGGCTTGAACG-3’ 
47 Schlesinger 
et al. (2005) 
0.94 
VEB F:5’-ACGGTAATTTAACCAGATAGG-3’ 
R:5’-ACCCGCCATTGCCTATGAGCC-3’ 
46 Schlesinger 
et al. (2005) 
0.97 
SFO F:5’-GTTAATCCATTTTATGTGAGG-3’ 
R:5’-CAGATACGCGGTGCATATCCC-3’ 
44 Schlesinger 
et al. (2005) 
0.94 
PER F:5’-ATGAATGTCATTATAAAAGC-3’ 
R:5’-AATTTGGGCTTAGGGCAGAA-3’ 
42 Weldhagen et 
al. (2003) 
0.93 
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4.3 RESULTS 
For the ESBL confirmatory phenotypic tests, 59.5% of the isolates tested positive 
with the double disc synergy test. One or more of the cephalosporins showed synergy 
towards the central clavulanic acid disc for each of these isolates. Cefepime appeared to be 
the most sensitive indicator cephalosporin with 77.3% of these isolates showing cefepime-
clavulanate synergy. This was closely followed by 75% ceftazidime-clavulanate synergy and 
54.5% and 0.1% for cefotaxime and cefpodoxime respectively. The Stenotrophomonas 
isolates exhibited nine distinct ESBL phenotypes (Fig 4.1) of which 31.8% showed synergy 
between clavulanic acid and cefepime, ceftazidime and cefotaxime (CPM-CAZ-CTX-AUG). 
 
 
Fig 4.1: Pie chart showing distribution of different ESBL phenotypes exhibited by the 
Stenotrophomonas maltophilia isolates using the double disc synergy tests. 
64 
 
As previously reported (Section 3.3), 58.6% and 27.1% of the isolates were resistant and 
intermediately susceptible to aztreonam respectively, of which 55% of these also displayed a 
positive DDST further confirming the possible production of ESBLs by these isolates. 
However, PCR amplification only allowed identification of the CTX-M group of ESBLs in 
four of these isolates (Fig 4.2 and Fig 4.3) all of which had the same ESBL phenotype (CPM-
CAZ-AUG). The CTX-M ESBLs amplified belonged to the CTX-M-1 and CTX-M-8 groups. 
Each of the four isolated showed amplification of genes from both groups. 
 
 
 
 
 
 
 
 
Fig 4.2: Gel picture of amplification of genes belonging to CTX-M 1 group. Amplicons are 
of the expected size of 490bp. Lane 1: molecular marker; Lane 2: nuclease-free water; Lanes 
3-8, 10: template DNA; Lane 9: empty 
490bp 
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Fig 4.3: Gel picture showing amplification of ESBLs belonging to CTX-M 8 group. 
Amplicons show expected amplicon size of 580bp. Lane 1: molecular marker; Lanes 2-6: 
template DNA; Lane 7: nuclease-free water. 
 
 
 
 
580bp 
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4.4 DISCUSSION 
In this study, we report the presence of CTX-M ESBLs in S. maltophilia isolated from 
the Eastern Cape environment. The issue of ESBL production in S. maltophilia is a 
controversial one. Several studies have reported double disk synergy test positivity in clinical 
isolates of this organism (Blahova et al., 1998; Canton et al., 1999; Hejnar et al., 2004) but 
Munoz Bellido and Garcia-Rodriguez (1998) suggest that these reactions could be explained 
by other properties of the L2 β-lactamase of S. maltophilia. More recent studies, making use 
of phenotypic and molecular methods have, however, further confirmed the presence of 
ESBLs in this species (Al-Naiemi et al., 2006; Hu et al., 2009). In this study, 59.5% of the 
isolates that showed resistance to the indicator cephalosporins were positive for ESBL 
production using the DDST (Jarlier et al., 1988). 
The Clinical and Laboratory Standards Institute (CLSI) recommends the use of more 
than one cephalosporin when using the disc diffusion method for the detection of ESBLs in 
order to increase the sensitivity of the tests because of the variable substrate affinities of 
different ESBL enzymes (CLSI, 2009). Cefotaxime is thought to be an adequate substrate for 
CTX-M enzymes which are more potent hydrolysers of cefotaxime than ceftazidime, while 
ceftazidime is a suitable substrate for the TEM and SHV variants. However some authors 
have suggested that if only one drug can be used, then cefpodoxime may be a more effective 
single indicator (Jarlier et al., 1988; Steward et al., 2001). In this study, about 99% of the 
isolates were resistant to cefpodoxime in the initial screening tests and only 0.1% of those 
isolates displayed cefpodoxime-clavulanic acid synergy. This may indicate that resistance is 
due to the L1 β-lactamase or other non-ESBLs or possibly other resistance mechanisms in S. 
maltophilia (Blahova et al., 1998).  
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The inclusion of cefepime in double disc synergy testing is thought to improve the 
sensitivity of the test especially in organisms that also produce Amp-C β-lactamases. 
Comparably with other studies (Tzelepi et al., 2000; Gupta et al., 2007; Mohanty et al., 
2010), cefepime was found to be the most effective indicator of ESBL production in the 
DDST in this study. No studies have confirmed the production of AmpC β-lactamases in S. 
maltophilia but given its multi-resistant nature, production of several β-lactamases, and 
ability to acquire resistance genes from other organisms, it may be worthwhile to include 
cefepime in the screening and confirmation of ESBLs in this organism to improve the 
sensitivity of the test. In addition, CTX-M ESBLs hydrolyse cefepime more efficiently than 
other ESBL types often with MICs in the resistant range (Sridhar, 2011). 
A little over a decade ago, investigations into extended spectrum β-lactamase 
enzymes almost exclusively revealed TEM and SHV types of ESBLs. However, the 
dynamics have changed with the CTX-M ESBLs increasingly becoming the predominant 
enzyme type isolated from Gram-negative organisms and it is being found more frequently in 
community isolates (Patterson and Bonomo, 2005; Livermore and Hawkey, 2005; Livermore 
et al., 2007). The PCR amplification of bla genes in this study revealed the presence of CTX-
M ESBLs in four of the S. maltophilia isolates. The amplicons detected were the expected 
size for enzymes belonging to the CTX-M 1 and CTX-M 8 groups. This is similar to results 
obtained by Al-Naeimi et al. (2006) and Lavigne et al. (2008) who reported the presence of 
CTX-M enzymes in clinical isolates of S. maltophilia. Al-Naeimi et al. (2006) identified the 
CTX-M gene as CTX-M-1 after sequencing while the CTX-M enzyme in the French study by 
Lavigne et al. (2008) was identified as CTX-M-15 following plasmid analysis. 
The CTX-M group of ESBLs is divided into five major groups based on amino acid 
sequences. Members of each group share greater than 94% amino acid similarity while there 
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is less than 90% similarity between distinct groups. CTX-M-1 group consists of six plasmid 
mediated enzymes: CTX-M-1, CTX-M-3, CTX-M-10, CTX-M-12, CTX-M-15 and FEC-1 
including some unpublished enzymes. CTX-M-2 group consists of eight plasmid mediated 
enzymes namely: CTX-M-2, CTX-M-4, CTX-M-4L, CTX-M-5, CTX-M-6, CTX-M-7, CTX-
M-20 and Toho-1. CTX-M-8 is the sole member of its group. CTX-M-9 group consists of 
CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16, CTX-M-17, CTX-M-19, CTX-M-21, CTX-
M-27 and Toho-2. CTX-M-25 group has two members: CTX-M-25 and CTX-M-26 (Bonnet, 
2004). 
Both enzymes in the Al-Naeimi et al. (2006) and Lavigne et al. (2008) studies belong 
to the CTX-M-1 group which correlates with our finding of ESBLs of the CTX-M-1 group. 
CTX-M-15 is by far the most frequently reported CTX-M ESBL around the world in both 
hospital and community isolates of Enterobacteriaceae, especially Escherichia coli urinary 
isolates (Woodford et al., 2004; Pitout et al., 2005; Pitout et al., 2007; Lewis II et al., 2007; 
Padimini et al., 2008). In South Africa, several studies have also reported the presence of 
CTX-M ESBLs in several Gram-negative organisms including P. aeruginosa and E. coli 
(Paterson et al., 2003; Ehlers et al., 2009; Peirano et al., 2011) but to the best of our 
knowledge this is the first description of CTX-M ESBLs in environmental isolates of S. 
maltophilia. The detection of these ESBLs in only four of the isolates tested may be due to 
several factors. The template DNA used in the PCR reactions were genomic DNA and as 
earlier discussed extended spectrum β-lactamase genes can be carried on plasmids, integrons 
or transposons. Further studies need to be done to determine if the isolates possess such 
mobile elements and the resistance genes they carry. 
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4.5 CONCLUSION 
Phenotypic detection of ESBLs in non-fermentative Gram negative bacilli is complex 
but with the use of molecular methods such as PCR, we have been able to confirm the 
presence of ESBLs in S. maltophilia isolated from this environment. The presence of these 
genes has significant implications for infection control specialists and microbiologists 
because laboratories do not routinely screen for the presence of ESBLs in this group of 
organisms. The occurrence of ESBLs in these organisms may therefore, be seriously 
underreported making nosocomial and opportunistic organisms such as S. maltophilia an un-
monitored reservoir of these genes with the potential to spread them to both community and 
hospital isolates. The possession of extended spectrum β-lactamases also further limits the 
already severely limited therapeutic options for the treatment of infections caused by this 
organism. 
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CHAPTER FIVE 
COMPARATIVE IN-VITRO ACTIVITY OF TRIMETHOPRIM-
SULFAMETHOXAZOLE AND THE NEW FLUOROQUINOLONES AGAINST 
EXTENDED-SPECTRUM BETA- LACTAMASE PRODUCING Stenotrophomonas 
maltophilia 
The production of extended-spectrum β-lactamases by any organism suggests that such 
organism is resistant to β-lactam group of antibiotics including penicillins, broad-spectrum 
and extended-spectrum cephalosporins and the monobactam, aztreonam while they remain 
susceptible to the β-lactamase inhibitors (Bradford, 2001, Falgas and Karageogopoulos, 
2009; Deepthi and Deepthi, 2010). Non-fermentative Gram-negative bacilli such as S. 
maltophilia have become increasingly important as causes of nosocomial and opportunistic 
infections in the last two decades and the production of ESBLs by these organisms poses an 
immense challenge for effective therapy (Looney et al., 2009). The ability of these bacteria to 
acquire various β-lactamases with different susbrate profiles and the selection of complex 
mutant enzymes that possess inhibitor-resistant phenotypes renders virtually all β-lactams 
ineffective (Al-Jasser, 2006a; Bush, 2010). 
Extended-spectrum β-lactamase genes are often carried on plasmids which also bear 
genes that encode for resistance to other classes of antibiotics such as aminoglycosides, 
fluoroquinolones, tetracyclines (excluding glycycyclines) and trimethoprim-sulfamethoxazole 
(Al-Jasser, 2006a; Bush, 2010; Falgas and Karageogopoulos, 2009; Pitout and Laupland, 
2008). Resistance to TMP-SMX is being described increasingly in S. maltophilia infections 
with reported resistance rates varying from different areas of the world (Toleman et al., 2007; 
Falgas et al., 2008). This has been linked to the possession of class 1 integrons bearing sul1 
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genes and insertion sequence (ISCR) common region elements bearing sul2 genes which are 
responsible for TMP-SMX resistance (Hu et al., 2011). This class 1 integrons have also been 
associated with production of ESBLs (Al-Jasser, 2006a, Perez et al., 2007; Bush, 2010; 
Phongpaichit et al., 2011) 
In this study, we compared the in-vitro susceptibilities of TMP-SMX and the 
fluoroquinolones, ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin 
against confirmed extended spectrum beta-lactamase producing S. maltophilia. The antibiotic 
susceptibilities were determined by disc diffusion method as previously reported (Section 
3.3) and phenotypic detection of ESBLs was done by the double disc synergy method 
(Section 4.3). As shown in Table 5.1 below, about 59.5% of the isolates were phenotypically 
confirmed as ESBL producers. Of the ESBL positive isolates, 70.5% were susceptible to 
TMP-SMX while 22.7% of them were resistant. Susceptibility to the fluoroquinolones ranged 
from 72.7% to 95.5% while resistance rate was 2.3% to each of the drugs. Levofloxacin was 
the most effective fluoroquinolone against the ESBL positive isolates while ciprofloxacin 
was the least effective with susceptibility of 72.7%. 
Table 5.1: Percentage susceptibilities of ESBL +ve and ESBL –ve isolates to TMP-SMX 
and the fluoroquinolones. 
  TMP-
SMX 
OFX CIP LEV MFX GAT 
ESBL 
+VE 
S (%) 
I (%) 
R (%) 
70.5 
6.8 
22.7 
86.4 
11.4 
2.3 
72.7 
25.0 
2.3 
95.5 
2.3 
2.3 
88.6 
9.1 
2.3 
93.2 
4.5 
2.3 
ESBL –
VE 
S (%) 
I (%) 
R (%) 
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Fig 5.1: Bar chart showing the comparative susceptibilities of TMP-SMX and 
fluoroquinolones against ESBL-positive and ESBL-negative S. maltophilia isolates. 
This data was analysed using Fischer’s exact test and p-value < 0.05 was considered 
as significant. The presence or absence of ESBL production did not have a significant effect 
on the susceptibilities of these S. maltophilia isolates to TMP-SMX or the fluoroquinolones 
(p-value >0.05 in all categories). Figure 5.1 is a graphical representation of the 
susceptibilities of the ESBL-positive and ESBL-negative isolates and it clearly shows the 
fluoroquinolones are almost equally effective against ESBL-positive and ESBL-negative 
isolates.  
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Although this study did not find any significant relationship between ESBL 
production and resistance to TMP-SMX and the fluoroquinolones, other studies and surveys 
done around the world have shown the tendency of associated resistance in community 
isolates of ESBL producing organisms (Woodford et al., 2004; Pitout et al., 2007; Pitout and 
Laupland, 2008). Studies examining the susceptibility profile of CTX-M-producing E. coli 
reported resistance to TMP-SMX up to 64% and resistance to cephalosporins up to 68%. 
Empirical therapy with cephalosporins and fluoroquinolones were also found to be associated 
with increased mortality (Ben-Ami et al., 2006; Rodriguez-Bano et al., 2006; Pitout and 
Laupland, 2008). In the present study, only one of the isolates found to possess CTX-M 
ESBLs after PCR was resistant to TMP-SMX. 
Some studies have determined that fluoroquinolone resistance in S. maltophilia is 
mediated by the chromosomal qnr gene and the genes that encode for the SmeDEF efflux 
pumps that lead to extrusion of fluoroquinolones (Shimzu et al., 2008, Sanchez et al., 2009; 
Sanchez and Martinez, 2010; Hernandez et al., 2011). However, in the extensive review of 
quinolone resistance by Hernandez et al. (2011) the authors describe the emergence of 
plasmid encoded qnr genes in various environmental bacterial pathogens. The genetic 
environment surrounding these genes reveals that they are integrated in complex sul1 type 
integrons and are associated with ISCR1 (Nordmann and Poirel, 2005). 
The presence of ESBLs, therefore, poses a unique challenge for the selection of 
appropriate empirical therapy. Prompt and effective use of the appropriate empirical 
antibiotics affects eventual treatment outcome but clinicians are now faced with the attendant 
co-existence of ESBLs and resistance to major antibiotic groups making the “magic bullet” 
even more difficult to find (Tumbarello et al., 2006; Perez et al., 2007) 
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CHAPTER SIX 
GENERAL DISCUSSION AND CONCLUSION 
Bacterial resistance to antimicrobial treatment is an emerging major public health threat 
facilitated by the widespread indiscriminate use of these antimicrobials in health care and 
community settings (Colodner, 2005). Subsequent to this, multidrug resistant organisms 
evolve due to increased antimicrobial selection pressure, from inherently or relatively 
susceptible organisms to more resistant strains thereby increasing the proportion of resistant 
strains of a particular organism. This selection of less susceptible strains tends to favour the 
emergence of free-living opportunistic pathogens that are resistant to antibiotics and even 
sensitive organisms begin to acquire new resistance mechanisms usually by the transfer of 
plasmids and transposons from less virulent organisms in the environment (French, 2010). 
The identification of putative resistance genes in environmental organisms is an issue that is 
just beginning to receive attention (Martinez, 2008). 
Opportunistic pathogens are pathogens that cause disease only in individuals who are 
susceptible to illness due to a compromise in their immune systems such as severely 
debilitated patients, cystic fibrosis patients and those infected with HIV (Berg et al., 2005). 
The non-fermentative Gram negative bacteria are playing an increasingly important role in 
these infections (Enoch et al., 2007). P. aeruginosa has long been the most important 
organism in this group but S. maltophilia has been named the third most important non-
fermentative Gram negative bacillus in opportunistic infections (Barchitta et al., 2009; Jones 
et al., 2003; Nyc and Matejkova, 2010). It is often difficult to differentiate between true 
infection and colonisation by this organism however; mortality rates attributable to S. 
maltophilia bacteremia are as high as 60% (Senol et al., 2002; Friedman et al., 2002; Enoch 
et al., 2007). The population at risk of infections due to this organism have also increased 
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considerably due to advances in medical therapeutic interventions such as the use of invasive 
therapeutic devices (central venous catethers, mechanical ventilation, haemodialysis) and 
increased utilization of broad spectrum antimicrobials (Senol, 2004; Al-Jasser, 2006b). It is 
also being reported in patients infected with HIV/AIDS (Calza et al., 2003) 
Treatment of infections due to S. maltophilia is challenging due to its multi-resistant 
status with the production of multiple β-lactamases which confer resistance to the β-lactams, 
aminoglycoside-modifying enzymes, multidrug efflux pumps and low outer membrane 
permeability which are responsible for resistance to aminoglycosides, quinolones and 
polymyxins. Recently the presence of sul genes responsible for resistance to TMP-SMX has 
also been described (Toleman et al., 2007; Chang et al., 2007). According to Sanchez et al. 
(2009) this intrinsic resistance phenotype is exhibited by both clinical isolates and 
environmental strains of the organism. 
The success of TMP-SMX as the agent of choice for the treatment of these infections 
has been attributed not only to its antibacterial effect but also to its immunomodulatory action 
which is associated with the induction of suppression of TNF-α (Nyc and Matejkova, 2010). 
Its efficacy can however be compromised by selection of resistant strains during long term or 
repeated administration or by colonization by an already resistant strain. Several studies have 
reported variable rates of resistance to TMP-SMX around the world (Betriu et al., 2002) and 
in this study, 28.2% of the isolates were resistant to the drug. This has significant 
implications in the Eastern Cape environment. TMP-SMX is used extensively as prophylactic 
treatment against Pneumocystis carinii pneumonia in HIV/AIDS patients and unfortunately, 
this group of patients are also susceptible to S. maltophilia infections due to their 
immunocompromised status. This may lead to the selection of resistant strains of S. 
maltophilia in these individuals due to prolonged exposure to TMP-SMX subsequently 
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making them more vulnerable to other opportunistic infections by TMP-SMX resistant S. 
maltophilia. On the other hand, as previously discussed the genes responsible for TMP-SMX 
resistance have been found on moblile elements associated with resistance genes to a variety 
of other antibiotics including fluoroquinolones. 
In conclusion, the growing burden of S. maltophilia as an important opportunistic 
pathogen cannot be overlooked. The high level of TMP-SMX resistance seen in these 
environmental isolates further buttresses the need for special attention on these organisms as 
possible reservoir of antibiotic genes. Furthermore, with the ongoing pandemic of HIV/AIDS 
and the continuous selective pressure exerted on these commensal organisms, community 
acquired multidrug resistant infections may increase. TMP-SMX still remains an effective 
drug for the management S. maltophilia infections if a tight rein is kept on its appropriate use. 
The newer fluoroquinolones however provide a suitable alternative in cases where TMP-
SMX is either unsuitable or ineffective. 
It remains to be determined how these environmental isolates acquired the CTX-M 
ESBLs. Their presence may indicate the increasing number of CTX-M positive isolates of 
other Gram negative bacteria in the community or the transfer of these resistance genes from 
hospital pathogens to environmental bacteria. The problem of multi-drug resistant Gram 
negative bacteria and extended-spectrum β-lactamases is not going to go away and infectious 
disease specialists can only stay a step ahead by continuous surveillance and the prudent use 
of antibiotics while research is ongoing on the development of new antibiotic compounds. 
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